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Abstract
Background: Obstructive sleep apnoea (OSA) is estimated to affect up to 1 billion people in
the world. Those who fail first-line continuous positive airway pressure (CPAP) therapy have
salvage treatment options available. Patient assessment can incorporate multidisciplinary
teams to better select therapy. Traditional parameters that define OSA severity do not always
correlate with symptoms of the disease. Newly identified pathophysiological “phenotypes”
of airway vulnerability, low arousal threshold, loop gain and muscle responsiveness may
explain the heterogeneity of OSA for up to two-thirds of patients. Little data exists on the
effectiveness of phenotyping in a real-world clinical setting for patients undergoing
contemporary management paradigms.

Aims and Hypothesis: To evaluate the prevalence of the four OSA phenotypic traits and
explore the clinical validity of endotyping in predicting future treatment outcomes. It is
expected that non-responders to treatment will have unfavourable non-anatomical
phenotypes.

Design: An observational prospective cohort study of 49 patients referred after failure of
CPAP for consideration of salvage therapy was conducted. Treatments included upper airway
surgery (n = 17), mandibular advancement splint (n = 7), positional therapy (n = 7), weight
loss (n = 4), nerve stimulation (n = 5) and combination therapy (n = 9). Treatment “success”
was defined using polysomnographic parameters and patient-reported outcome measures of
sleepiness and function. Phenotypic traits were analysed according to these outcomes.

Results: Nearly all surgical patients had unfavourable loop gain (LG1 > 0.72), which improved
after surgical treatment (p < .05). Patients who had decreased sleepiness (Epworth Sleepiness
Scale reduction ≥ 3, total score < 10, p = .01) after any treatment had favourable traits of low
loop gain, lower arousal threshold and lower muscle compensation. There may be a potential
role for phenotyping in predicting expected outcomes from salvage treatment for OSA,
although more prospective clinical data is required to further investigate its utility and
relevance.
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1. Background
Adult obstructive sleep apnoea (OSA) is a prevalent condition affecting up to 1 billion people
in the world1 and is characterised by repeated episodes of partial or complete upper airway
obstruction during sleep. This results in oxygen desaturation and carbon dioxide retention,
leading to arousal from sleep in an effort to maintain airway patency2. Repeated oxygen
desaturations and arousals throughout the night lead to primary sleep deprivation,
neurocognitive dysfunction and secondary adverse cardiometabolic effects2, 3. Common
nighttime symptoms experienced in adults include snoring, choking or gasping, while daytime
symptoms include somnolence, poor concentration and morning headaches4, 5.

Diagnosis is made with polysomnography (PSG), ideally performed overnight in a sleep
laboratory or alternatively as a home-based study6. A battery of physiological measurements
are recorded, including the number of complete and partial obstructive events per hour as
the apnoea/hypopnoea index (AHI), oxygen desaturations per hour as the oxygen
desaturation index (ODI) and the lowest oxygen saturation (Lsat). A diagnosis of OSA in adults
is conventionally made based on an AHI of 5 (events per hour), with further severity
stratification into mild OSA defined by an AHI of 5-14, moderate 15-30 and severe over 307.

The existing treatment options for OSA can be summarised into lifestyle modifications (such
as weight loss), positional therapy, positive airway pressure, airway mandibular advancement
splint (MAS) devices and surgical therapy8. Continuous positive airway pressure (CPAP) is firstline therapy in adult OSA treatment; failure of treatment is commonly due to problems with
adherence or tolerance, with varying rates reported in the literature 9. For these patients,
other airway devices such as MAS or tongue retaining devices can be explored10. Salvage
surgery is an option in those who fail first-line treatment with techniques such as “pre-phase”
nasal surgery11,

12,

contemporary variants of uvulopalatopharyngoplasty (UPPP) with or

without palatal advancement13-15 and tongue reduction or suspension16-20.

Research demonstrates that the traditional polysomnographic diagnostic definition based on
AHI is imperfect21, particularly regarding cardiovascular risk stratification in OSA. Equally
there is a growing acceptance that CPAP cannot be used as a “one-size fits all” treatment in
13

clinical practice. This has led to a new model of OSA, characterised by pathophysiological
“phenotypes” expressed to differing degrees in each individual. These accepted phenotypic
traits, or more accurately, “endotypes”, are: (1) airway vulnerability, (2) low arousal
threshold, (3) loop gain and (4) muscular excitability22, 23. It is proposed that established and
emerging treatments for OSA have roles to play in modifying the disease burden based on
these phenotypes, and it is therefore possible to personalise therapy based on the individual
profile of OSA for each patient23, 24.

This chapter identifies the gap in the literature surrounding the role of personalised
management of OSA and how established treatment pathways can be utilised as a part of this
new paradigm.
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2. Anatomy and Physiology of Obstructive Sleep Apnoea
2.1 Upper Airway Anatomy25
The upper airway is comprised of the nasal airway, oral cavity, pharynx (divided into three
levels, the nasopharynx, oropharynx and laryngopharynx) and larynx. Contiguous with this is
the lower airway, comprised of the trachea, bronchi, bronchioles and subsequent divisions
thereof.

The nasal airway is relatively fixed in terms of its anatomical structure and does not fluctuate
significantly during sleep. Its key boundaries are the external and internal nasal valves, nasal
septum and inferior turbinates. The nasopharynx sits immediately posterior to the nasal
cavity and continues as the oropharynx.

The oral cavity and oropharynx are formed from fixed and dynamic structures. Fixed (“hard”)
structures include the facial skeleton (maxilla, mandible), teeth and the hard palate. Dynamic
(“soft”) structures include the tongue, adenoid (if present), palatine and lingual tonsils and
soft palate including the uvula. The oropharynx sits at the junction of the nasopharynx and
oral cavity.

The tongue is composed of four paired intrinsic muscles and four paired extrinsic muscles.
Intrinsic muscles (superior longitudinal, inferior longitudinal, vertical and transverse) are
responsible for altering the shape of the tongue while retaining a constant volume. Extrinsic
muscles (genioglossus, hyoglossus, styloglossus, palatoglossus) protrude, retract and draw
the sides of the tongue down and up respectively. The tongue is tethered to the mandible
and hyoid bone, the latter of which also suspends the floor of mouth, suprahyoid and
infrahyoid musculature.

The soft palate and uvula is a complex unit that incorporates multiple muscle insertions into
a singular fibrous sheet known as the palatal aponeurosis 26. The soft palate can be divided
into a proximal and distal segment, which is separated by the palatal genu. It can be thought
of as being comprised of several muscular slings. The tensor palati is responsible for tensing
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the palate to enable it to retain its shape when being elevated or depressed by other muscles.
The levator palati pulls the palate upwards and backwards. The palatoglossus (as discussed
above) raises the sides of the tongue and is sphincteric at the oropharyngeal entrance. The
palatopharyngeus has an anterior head that elevates the pharynx and arches the relaxed
palate, and a posterior head that depresses the tensed palate.

Figure 1. Anatomic features contributing to OSA with impacts on the retropalatal (RP) and retroglossal (RG)
spaces. Adapted from Gottlieb DJ, Punjabi NM. Diagnosis and Management of Obstructive Sleep Apnea: A
Review. Jama. 2020 Apr 14;323(14):1389-40027.
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The pharynx can be considered a muscular tube attached to the above structures. The space
within this tube can be divided according to adjacent relations from superior to inferior as the
nasopharynx, oropharynx and laryngopharynx. The muscular wall comprises three sheets of
muscle that are the superior, middle and inferior constrictors overlapping posteriorly like
three stacked cups. These are supported by three smaller muscles, the palatopharyngeus
(discussed above), salpingopharyngeus and stylopharyngeus. Around the level of the superior
constrictor and palatopharyngeus, there is also a palatopharyngeal sphincter (also known as
Passavant’s ridge) that moves the posterior pharyngeal wall forward to assist in closing the
nasopharynx from the oropharynx (although closure is predominantly achieved by the soft
palate). In sleep medicine, the part of the pharynx posterior to the palate is referred to as the
retropalatal airway and that posterior to the tongue is known as the retroglossal (or
retrolingual) airway.

The adenoid, palatine and lingual tonsils make up Waldeyer’s ring, which is a nexus of
lymphoid tissue that is most prominent in childhood and recedes into adulthood. In certain
adult patients these tissues remain prominent and can also contribute to airway collapse in
sleep. The adenoids sit in the posterior nasopharynx and superior to Passavant’s ridge and
are rarely identified in adults. The palatine tonsils sit nestled between the palatoglossus and
palatopharyngeus muscles (known as the anterior and posterior tonsillar pillars). The lingual
tonsils are located at the base of the tongue in the vallecula and at the same level of the
epiglottis. The epiglottis is draped in mucosa that extends across the sides of the laryngeal
inlet as the aryepiglottic folds and border the pyriform recesses along the side of the posterior
laryngopharynx.
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Figure 2. Posterior pharyngeal anatomy with key structures. Adapted from Olszewska E, Woodson BT. Palatal
anatomy for sleep apnea surgery. Laryngoscope Investigative Otolaryngology. 2019. 26

Palatine

18

2.2 Anatomical Sites of Collapse and Risk Factors for OSA
The upper airway does not collapse homogenously but is dependent on surrounding tissue
pressure exceeding the intraluminal pressure. Airway evaluation during wakefulness and
sleep has been achieved with direct endoscopy28 and dynamic radiological imaging
techniques (including computed tomography (CT)29 and magnetic resonance imaging (MRI)30)
to identify key points of vulnerability at the retropalatal and retroglossal levels, as well as the
lateral pharyngeal walls.

Larger volumes in the soft palate, tongue and parapharyngeal tissue have been identified in
patients with OSA31. In particular, the lateral pharyngeal walls contribute to the largest fluxes
in lateral airway diameter between inspiration and end-expiration as compared to the anteroposterior dimension32.

One of the most frequent comorbidities identified in adults with OSA is obesity. An increase
of body mass index (BMI) by one standard deviation triples the prevalence of OSA (Wisconsin
Sleep Cohort Study)3. An increase in regional adiposity has been linked to fat deposition in
critical upper airway soft tissue structures33, 34. Studies have demonstrated obese apnoeics
have greater adiposity in tongue tissue compared to normal controls35. Recent evidence
reveals the complex interaction between OSA and obesity, with data demonstrating a large
reduction in BMI does not correlate with a comparable improvement in AHI. To add
complexity, not all obese patients have OSA36, 37.

Body position during sleep has an impact on OSA, with the oropharynx and tongue being
particularly vulnerable to collapse in a supine position due to the effects of gravity compared
with a lateral or upright position38. The palate can also be directly observed to collapse during
a Müller manoeuvre28, explained in more detail below.

Craniofacial features have been linked to patients with OSA, with smaller mandibles39,
caudally positioned hyoid bones40 and retroposed maxillae41 all significantly more prevalent
in apnoeics. Cephalometric measurements that have been used to identify patients at risk
include sella-nasion to subspinale (SNA), sella-nasion to supramentale (SNB) and mandibular
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plane-hyoid (MPH) distances42. Patients with smaller SNA/SNB and longer MPH are more
likely to have OSA43, 44.

There is a difference in gender in OSA, with more men affected overall and women having
lower AHIs compared to men of equivalent BMI45. Women more likely have a history of
depression and hypothyroidism at the time of diagnosis of OSA 46. Men generally have longer
airways, larger neck and soft tissue structures that all increase collapsability47. Data
supporting the conclusion that hormonal levels may also play a part is mixed, with some
studies suggesting there is a link between post-menopausal women and OSA48, and others
finding no association49.

Ethnic differences have been observed in OSA, with likely links to rates of obesity, craniofacial
morphology, dietary habits and lifestyle50. As an example, Asian men have lower BMI for any
degree of OSA compared with Caucasians, a finding attributable to craniofacial features51.
However, the ratio of obesity to craniofacial bony size is comparable between these
populations for a given severity of OSA, suggesting that patients with skeletal restriction are
likely more sensitive to an increase in BMI52. In Polynesians, nasal aperture and retrognathia
were correlated with OSA severity compared to Caucasians 50.

Age also impacts OSA, with older patients tending to have more severe disease compared to
younger

counterparts.

In

addition,

genioglossus

muscle

responsivity

decreases,

parapharyngeal fat pad size increases and jaws are relatively more retrognathic in older men.
In older women, pharyngeal length is relatively greater than younger women 53.
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2.3 Biomechanics of the Upper Airway
The subdivisions of the upper and lower airway has been expressed in the form of a Starling
resistor model54, even though this over-simplifies the airway, with a collapsible segment
(soft/dynamic tissues) bounded by two rigid segments upstream (nasal cavity) and
downstream (larynx/trachea)55. The rigid segments have a fixed diameter and resistance, with
varying intraluminal pressure according to the phase of respiration in sleep (expressed as P US
and PDS).

Figure 3. Schematic representation of the Starling resistor model of the upper airway. The collapsible segment is
bordered by rigid upstream and downstream segments (A). The airway is completely occluded when P CRIT exceeds
PUS and PDS (B). The airway is flow limited when PCRIT exceeds PDS but is less than PUS, so can still equilibrate and
open and close (C). The airway is patent when both P US and PDS exceed PCRIT (D). Adapted from Pham LV, Schwartz
AR. The pathogenesis of obstructive sleep apnea. Journal of thoracic disease. 2015;7(8):1358. 54

In this model, there is a critical closing pressure (P CRIT) at which the collapsible segment will
become completely occluded, thereby ceasing all airflow. If PCRIT is less than PUS but greater
than PDS, this creates a flow-limited system whereby some occlusion would occur within the
collapsible segment, but as the segment adjacent to the occlusion equilibrates to PUS, this
rises above PCRIT and subsequently re-opens the segment downstream to the occlusion. This
causes the airway to cycle between an open and closed state at a pressure equivalent to PCRIT.
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While pressure remains constant, airflow will do so as well and thus plateaus at a maximal
level (Vmax), calculated as shown below using Ohm’s law56, 57.

𝑉𝑚𝑎𝑥 =

𝑃𝑈𝑆 − 𝑃𝐶𝑅𝐼𝑇
𝑅𝑈𝑆

Airflow limitation is important in the pathogenesis of OSA as it is responsible for two differing
strains on the respiratory system. One, resistance in the airways is increased significantly in
the flow-limited state (up to 20-40 cmH2O/L/s) when compared with the non-flow-limited
state (1-2 cmH2O/L/s). Two, further load is imposed during any period of flow limitation due
to exertion of increasing effort of inspiration without ever increasing inflow, hence wasting
pressure generated by the muscles of respiration54.

Figure 4. Effects of varying upstream pressure on inspiratory flow. P CRIT is represented by the dashed line. At PUS
4cmH2O, this is less than PCRIT and so the airway is closed. At PUS 6 and 9cmH2O, the PUS is greater and so there
is flow, but this is limited as PDS falls below PCRIT during inspiration. This results in flow limitation in the form of a
plateau at Vmax (arrows). At PUS 12cmH2O, PUS and PDS remain above PCRIT and so there is no further flow
limitation. Adapted from Pham LV, Schwartz AR. The pathogenesis of obstructive sleep apnea. Journal of thoracic
disease. 2015;7(8):1358.54

Multiple studies demonstrate that PCRIT is a sensitive and specific marker to distinguish
patients with OSA56-64. The diagnosis of OSA is strongly linked with patients who have a P CRIT
of -5cmH2O or above while higher PCRIT correlates with disease severity. Likewise, treatment
to decrease PCRIT below -5cmH2O is effective in improving OSA severity or even resolving
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disease56, 65. This has implications for management, and PCRIT’s usefulness as a phenotypic
marker will be explored in chapter 2.

2.4 Sleep Patterns in Normal Humans
The architecture of normal sleep can be divided into two states based on
electroencephalography (EEG), electrooculography (EOG), electromyography (EMG) and
behavioural features: non-rapid eye movement (NREM) and rapid eye movement (REM)
sleep. During an episode of sleep, these two states alternate cyclically approximately every
90-120 minutes66.

Figure 5. Sleep hypnogram of a normal adult for a complete night of sleep. W = wakefulness, R = REM sleep,
1/2/3 = NREM sleep stages 1/2/3.

NREM sleep can be divided into three sleep stages (N1, N2, N3). The arousal threshold (to
wake someone from sleep) is lowest in N1, and highest in N3, representing deeper sleep.
NREM is characterised by synchronous cortical EEG traces (sleep spindles, K complexes and
slow waves are features) along with reduced muscle tone67.

During REM sleep there are two main forms; tonic and phasic REM sleep. Tonic REM sleep is
characterised by muscle atonia and desynchronisation of the EEG. Phasic REM sleep is
characterised by bursts of rapid eye movements accompanied by phasic twitches of
peripheral muscles. Dreaming is common during REM sleep68 - in essence, the brain is
activated while the body remains paralysed66.

Autonomic nervous system function fluctuates depending on the state of sleep. During NREM,
parasympathetic activity is increased while sympathetic activity remains similar to the awake
state. During tonic REM, parasympathetic activity is also increased while sympathetic activity
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is decreased. Finally, during phasic REM sympathetic activity is significantly increased and
predominates despite increased parasympathetic activity69.

Patterns of respiration during sleep are noticeably different to wakefulness. There are two
main forms of control of breathing during wakefulness, being the metabolic (or automatic)
and voluntary (or behavioural). During sleep the voluntary system is removed and breathing
is driven entirely by the metabolic system, which is dependent on the respiratory control
mechanism located in the medulla of the brainstem69. Consequently, during sleep, respiratory
rate is reduced due to a combination of loss of voluntary control and increased airway
resistance from muscle hypotonia. The latter is particularly significant in REM during the tonic
phase, while muscle atonia further increases airway resistance.

In terms of metabolic control of sleep, hypoxic ventilatory drive is reduced during NREM and
even more so during REM sleep. Hypercapnic ventilatory response is likewise reduced during
NREM and essentially absent in REM sleep, meaning a larger carbon dioxide concentration
(pCO2) is required to trigger breathing during sleep70. When the ventilatory drive reaches a
certain threshold, arousal from sleep is triggered as a protective mechanism to bring the
individual back to wakefulness which is the primary reason for fragmented sleep in patients
with OSA71. This definition is further expanded upon in the following chapter.
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2.5 Airway Muscle Physiology During Sleep
Muscle collapsibility is increased during sleep due to various sleep states and muscle tonic
activity72, affecting the rigidity of and patency of the upper airway.

Remmers initially described the genioglossus as a driver to maintain oropharyngeal patency73.
It acts as an oropharyngeal dilator and has been noted to have phasic and tonic activity during
REM sleep74, with significant impact on pharyngeal pressures 75. Likewise there is phasic
activity noted in other associated airway dilating muscles in the upper airway, including the
geniohyoid76, pharyngeal constrictors77, 78, alae nasi and posterior cricoarytenoid muscles79.

Muscle hypotonia is most pronounced at the transition from wake to sleep, with several
studies demonstrating decreased tone in the genioglossus, geniohyoid, tensor palati, levator
palati and palatoglossus at sleep onset. There is a similar trend seen in the main muscles of
respiration, the diaphragm and intercostal muscles. When subjected to occlusion, the upper
airway dilators have been demonstrated to be preferentially activated during the process of
arousal compared with the diaphragm80, 81. The strength of this dilating effect is weaker in
sleep than in wakefulness, and it has been suggested patients with OSA may have an even
weaker muscular response in sleep compared to normal patients and thus be predisposed to
airway collapse82. This has been illustrated with increased compensatory genioglossus activity
in patients with OSA while awake compared with normal controls 83.
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3. Clinical Evaluation and Diagnosis of Obstructive Sleep
Apnoea
Patients who have OSA may present with upper airway symptoms (snoring, choking, gasping),
sweating during sleep, generalised fatigue, daytime somnolence, headaches, dry mouth and
sleep disturbance. A proportion may have coincident hypertension, diabetes, arrhythmia or
other cardiovascular comorbidities. Medical history may reveal motor vehicle accidents,
obesity or issues with general anaesthesia and a family history of OSA or snoring.

Despite these well-known symptoms a significant proportion of patients can present with
non-specific symptoms, and even more will never present, with an estimated 5% of the world
population living with undiagnosed OSA3,

84.

The Australian Sleep Association (ASA) has

generated an algorithm based on the combination of screening questionnaires to stratify
patients into high or low risk of OSA and PSG testing to confirm or refute the diagnosis 85.
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Figure 6. Algorithm for diagnosing suspected OSA. Adapted from Douglas JA, Chai-Coetzer CL, McEvoy D, Naughton MT, Neill AM, Rochford P, et al. Guidelines for sleep studies
in adults – a position statement of the Australasian Sleep Association. Sleep Medicine. 2017;36:S2-S22.85

3.1 Questionnaires
There are multiple validated OSA symptom-focused questionnaires published in the
literature. The Epworth Sleepiness Scale86 (ESS) is an 8-item scale that patients answer on a
4-point basis (0-3), the sum of which quantifies a patient’s daytime sleepiness. A score of 0-8
is considered normal, 9-10 is borderline, and >10 is excessive daytime sleepiness. The Snoring
Severity Scale87 (SSS) is a 3-item questionnaire that the bed partners of patients answer on a
4 point scale (0-3), quantifying loudness, length and frequency of snoring. The Functional
Outcomes of Sleep Questionnaire88 (FOSQ) is a 30-item questionnaire on a 4-5 point scale
that quantifies the impact of sleepiness on a patient’s life from a functional perspective.
Others are directed at different measures such as insomnia, sleep patterns and sleep
quality89.

A number of questionnaires have been specifically evaluated for their feasibility,
generalisability and accuracy as screening tools for OSA. An ideal screening test should have
high sensitivity and negative predictive value90 in order to “rule-out” disease. The Berlin
questionnaire is an 11-item form that is less frequently used and has a sensitivity of 86% in
primary care patients and 57-68% in sleep laboratory patients91, 92. STOP-BANG (Snoring,
Tiredness, Observed apnoeas, blood Pressure, BMI, Age, Neck circumference, Gender) is an
8-item questionnaire developed as an anaesthetic screening tool. It utilises a 2 point scale (01) that has a sensitivity of 87% in identifying patients at risk of having moderate-severe OSA
with a score 393, 94. Finally, the OSA50 (Obesity, Snoring, Apnoeas, aged >50 years) is a 4item questionnaire scored out of 10 (O, S worth 3 points and A, 50 worth 2 points each)
developed as a primary care tool in Australia. A score of 5 and a 3% ODI 16 had sensitivity
and specificity >80% in identifying OSA95.

The use of each questionnaire is at the discretion of the treating clinician in order to answer
specific clinical questions relevant to their practice. In Australia, prerequisite scores must be
met prior to ordering of investigations such as PSG according to the Medicare Benefits
Schedule96. All described questionnaires can be used at initial and follow-up appointments to
risk-stratify patients or track response to treatment.

3.2 Polysomnography
If the diagnosis of OSA is suspected, medical practitioners can refer patients to undergo PSG
testing. PSG is the primary tool used to diagnose OSA. It can be applied as an initial diagnostic
study, an interventional study (e.g. to assist in titration of CPAP or nerve stimulator devices)
or a follow-up study after treatment. Depending on the type of the study multiple parameters
can be measured, including EEG, EOG, oronasal pressures (or CPAP pressures during a
titration study), cardiac (using electrocardiography – ECG), jaw movements, respiratory and
limb movement activity (using EMG)67. Body position monitors also allow documentation of
patient position (lateral, supine or prone) throughout the course of the night.

The ASA guidelines outline 4 main types of sleep study85:
1. Type 1 tests are in-laboratory PSG studies, routinely attended by a sleep technician
and allow for recording of the greatest amount of physiologic signals85.
2. Type 2 tests are home-based portable PSG studies that are not attended by trained
technical staff. However they may be set-up by a sleep technician either in-lab or at
home prior to the study. There is a higher chance of underestimating the severity of
OSA (<10%), typically due to signal loss, but this may not significantly alter treatment
advice85.
3. Type 3 tests are limited channel studies that record only a few variables and do not
usually allow for sleep staging. These have at least 4 variables, typically including
oximetry, respiratory effort (thoracoabdominal movements), airflow, head and body
position, jaw movements, ECG, tonometry (marker of autonomic control), actigraphy
and sound85.
4. Type 4 tests only measure 1 or 2 variables, using oximetry, heart rate or airflow. Of
these, oximetry is the most informative, reliable and accurate, providing key
correlates of hypoxaemia85.

Type 3 and 4 studies are most suitable to use in populations that have no significant cardiorespiratory comorbidities. Patients should have a high pre-test probability of the diagnosis of
OSA as determined by screening tools that have high sensitivity and negative predictive values
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(rule-out tests as discussed above). Health services which have limited access to type 1 and 2
studies may use these.

Figure 7. Example of data traces used in a patient with OSA. Note the drops in SpO2 associated with snoring,
interruptions in airflow and thoracoabdominal movements. Adapted from Edwards BA, O'Driscoll DM, Ali A,
Jordan AS, Trinder J, Malhotra A, editors. Aging and sleep: physiology and pathophysiology. Seminars in
respiratory and critical care medicine; 2010: © Thieme Medical Publishers.53

SpO2

3.3 Respiratory Events
While EEG, EOG and EMG traces are primarily used for staging sleep, events that occur
throughout the night need to be noted. These include apnoeas, hypopnoeas, oxygen (O2)
desaturations, arousals and body movements. Respiratory events are often divided according
to the stage of sleep in which they occurred, usually either NREM or REM.

The most crucial for the diagnosis of OSA are apnoeas and hypopnoeas, which are complete
and partial cessations of airflow respectively. An apnoea is defined when both97:
1. There is a drop of 90% drop in the peak signal flow as detected by pressure monitors
(oronasal thermal sensors, CPAP device flow), and
2. This drop is sustained for 10 seconds.
A hypopnoea is defined when the following criteria are all met97:
1. There is a drop of 30% in the peak signal flow, and
2. This drop is sustained for 10 seconds, and
3. There is a 3% O2 desaturation from baseline OR there is an associated arousal.
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The AHI is the average number of apnoeas and hypopnoeas per hour over the course of the
night. An AHI of 5-14 constitutes mild OSA, 15-30 is moderate and 30 is severe7. Events can
be defined as obstructive (due to increased upper airway resistance) or central (due to
reduction in ventilatory effort) depending on their antecedent cause. An obstructive event is
associated with a flattening of the pressure waveform during inspiration, often accompanied
by snoring and paradoxical thoracoabdominal wall movements, while a central event will not
have any of the above97.

An additional event that is sometimes incorporated in sleep studies is Respiratory EffortRelated Arousal (RERA), which refers to arousals from sleep that are caused by increasing
respiratory effort that do not fall into either apnoea or hypopnoea criteria. The RERA is
defined when there is a sequence of breaths 10 seconds associated with increasing
respiratory effort (measured on EMG) or flattening of the inspiratory pressure curve. The
respiratory disturbance index (RDI) is measured as the sum of AHI and RERA index 97.
In the past there has been some disagreement between the use of a threshold of 2%, 3%
or 4% O2 desaturation as an event98. This has been investigated and 3% has found to be the
best performing marker across BMIs >25kg/m2 when detecting moderate to severe OSA99,
while 4% is a better predictor of cardiovascular risk100. The American Academy of Sleep
Medicine (AASM) 2018 guidelines utilise the standardised threshold as 3% based on this
evidence101. The ODI is an index of number of desaturations per hour over the course of a
night.

Limb movements are recorded using an EMG electrode on the tibialis anterior muscle on the
leg or extensor digitorum on the hand. These must not be associated with a respiratory
disturbance to be considered an event. They can also be measured in terms of events per
hour as the periodic limb movement (PLM) index 97.

The output of a sleep study can be summarised in terms of the indices described above and
graphically as a hypnogram. This displays the stages of sleep across the course of the night
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along with the timestamps of any respiratory events that may have occurred. It allows easy
interpretation for clinicians to correlate between sleep stage-specific events and associated
desaturations or limb movements.

Figure 8. Sample patient PSG summary for clinical interpretation including hypnogram, body position, events and oxygen
saturation.

While the PSG has been conventionally used for the measurements described above, there is
a wealth of information contained within the raw data that can be used for novel and clinically
relevant analysis of OSA, particularly in the burgeoning field of precision (or personalised)
medicine in OSA102, including phenotyping/endotyping.
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3.4 Comprehensive Upper Airway Evaluation
An increasing part of the practice of sleep medicine is incorporating a comprehensive upper
airway evaluation in conjunction with an otolaryngologist. This involves a thorough oral
examination for malocclusion, palatal phenotype26, 103, Friedman tongue grade and tonsillar
hypertrophy104 followed by nasendoscopy either conducted awake in the office or with a
sedative in what is known as drug induced sleep endoscopy (DISE) 28, 105. This enables the
evaluation of possible anatomical planes of collapse in vivo, which can help identify patients
who would benefit from certain anatomical treatments such as MAS or upper airway surgery.

Figure 9. Friedman tongue grade (FTG). (a) FTG I, with uvula and tonsils/pillar visible. (b) FTG IIa, with most of
uvula but not tonsils/pillar. (c) FTG IIb, entire soft palate to base of uvula. (d) FTG III, some of soft palate, distal
end absent. (e) FTG IV, hard palate only. Adapted from Friedman M, Salapatas AM, Bonzelaar LB. Updated
friedman staging system for obstructive sleep apnea. Sleep-Related Breathing Disorders. 80: Karger Publishers;
2017. p. 41-8.104
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Transoral examination can reveal the presence of malocclusion or craniofacial abnormalities,
which are associated with OSA106. Hard palate features such as a narrow or high arch can be
indicative of maxillary constriction (which may increase nasal resistance107, 108). The soft
palate phenotype is more easily evaluated with nasendoscopy (described below). Friedman
tongue grade is used to approximate obstruction at the oropharyngeal level and is
determined by the tongue’s position relative to the tonsils/tonsillar pillars, uvula, soft palate
and hard palate. It is similar to the Mallampati system but evaluates the tongue while it is in
a neutral position within the mouth104. Tonsil grade is also noted, given its propensity to
generate oropharyngeal collapse and its significance in compromising airway space109.

Figure 10. Tonsil grade. (a) Grade 0, no tonsillar tissue. (b) Grade 1, within the pillars. (c) Grade 2, extended to
the pillars. (d) Grade 3, extended beyond the pillars. (e) Grade 4, extended to the midline. Adapted from Friedman
M, Salapatas AM, Bonzelaar LB. Updated friedman staging system for obstructive sleep apnea. Sleep-Related
Breathing Disorders. 80: Karger Publishers; 2017. p. 41-8.104
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Nasal examination is conducted externally with anterior rhinoscopy and internally through
nasendoscopy. Key features contributing to nasal resistance include internal and external
nasal valve patency, inferior turbinate hypertrophy and septal deviation 110. The presence of
allergic rhinitis is also a treatable factor in facilitating other therapies in OSA111.

Nasendoscopy is then continued to evaluate the soft palate, which has been divided into 3
main subtypes by Woodson et al, based on the gradient of the genu relative to the posterior
pharyngeal wall, with a more vertically oriented palate more amenable to a surgical
procedure such as transpalatal advancement103.

Figure 11. Palate grade. Patients with a vertical palate are amenable to procedures such as transpalatal
advancement. Adapted from Woodson BT. A method to describe the pharyngeal airway. The Laryngoscope.
2015;125(5):1233-8103.

Lingual tonsil grade is most easily evaluated next as a possible cause of retroglossal
obstruction, with the tongue relaxed, then protruded104.

Figure 12. Lingual tonsil grade. (a) Grade 0, no lymphoid tissue. (b) Grade 1, scattered lymphoid tissue. (c) Grade
2, lymphoid tissue covering tongue base, limited vertical thickness. (d) Grade 3, lymphoid tissue covering entire
tongue base, vertical thickness 5-10mm. (e) Grade 4, lymphoid tissue covering entire tongue base, rising to or
above tip of epiglottis, approximately 1cm in height. Adapted from Friedman M, Salapatas AM, Bonzelaar LB.
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Updated friedman staging system for obstructive sleep apnea. Sleep-Related Breathing Disorders. 80: Karger
Publishers; 2017. p. 41-8.104

Dynamic manoeuvres are employed to visualise collapse in various anatomical planes under
direct vision. A simple full jaw thrust can be employed to mimic the effect of a 70% (maximally
titrated) MAS. The Müller manouevre was initially described by Borowiecki and Sassin112 and
involves forced inspiration against a closed mouth and nares, thereby inducing negative upper
airway pressures. Woodson’s hypotonic method113 involves maximal expiration to induce a
state akin to a completely flaccid and atonic airway. These manoeuvres are often conducted
at the retropalatal and retroglossal levels, and are further augmented when conducted in a
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supine position and possibly during sedation, more accurately mimicking the appearance of
the airway in sleep28.

Figure 13. Woodson’s Hypotonic Method. Airway structure is better defined by controlling for physiologic variables. Adapted
from Fairbanks DN, Mickelson SA, Woodson BT. Snoring and obstructive sleep apnea: Lippincott Williams & Wilkins; 2003 114.

𝑆𝑖𝑧𝑒𝑥 = 𝑓(𝑆𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑥 + 𝑀𝑢𝑠𝑐𝑙𝑒𝑇𝑜𝑛𝑒𝑥 + 𝐴𝑖𝑟𝑓𝑙𝑜𝑤𝑥 )
𝑥 = 𝑚𝑜𝑚𝑒𝑛𝑡 𝑖𝑛 𝑡𝑖𝑚𝑒
𝑤ℎ𝑒𝑛 𝑀𝑢𝑠𝑐𝑙𝑒𝑇𝑜𝑛𝑒 𝑎𝑛𝑑 𝐴𝑖𝑟𝑓𝑙𝑜𝑤 = 0
𝑆𝑖𝑧𝑒𝑥 = 𝑓(𝑆𝑡𝑟𝑢𝑐𝑡𝑢𝑟𝑒𝑥 )
Given the relative complexity of upper airway anatomy and the possible areas of collapse,
there has been a need to standardise the examination. One simple classification system that
has been proposed to summarise the findings from airway endoscopy is the Velum,
Oropharynx, Tongue, Epiglottis (VOTE) classification, allowing assessors to document the
degree of collapse in each anatomical area of interest115.

Table 1. The VOTE Classification. Adapted from Kezirian EJ, Hohenhorst W, de Vries N. Drug-induced sleep
endoscopy: the VOTE classification. European Archives of Oto-Rhino-Laryngology. 2011;268(8):1233-6.115

Structure

A-P

Configuration
Lateral

Concentric

Velum
Oropharynx
Tongue base
Epiglottis
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4. Current Treatment Paradigms for Obstructive Sleep Apnoea
OSA should be treated as chronic disease with the treatment goal being mitigation of longterm cardiovascular effects and reduction of daytime symptoms such as sleepiness. Other
reasons that patients request treatment are for social and quality of life reasons such as
snoring and partner disturbance116.

OSA is a heterogenous disease and there is a need to consider a range of treatments due to
patient anatomical, physiological and social factors. There is a benefit in a multidisciplinary
approach to managing OSA, as quite frequently there are treatment options that patients and
even clinicians will not always consider in isolation117.

4.1 CPAP
The accepted first-line treatment for adults with moderate or severe OSA is CPAP 116. This
comes in various forms, including nasally delivered CPAP, oral and full-face masks (depending
on pressure requirements, patient anatomy, finances and preference). At the initial
prescription of CPAP patients should attend the sleep laboratory for a titration study to
determine the optimum pressure required to control their OSA. The forms of ventilation
pressure delivery can be fixed (conventional CPAP) or variable including autotitrating (APAP)
and bilevel (BiPAP) modes that can be considered in select patients.

Treatment failure occurs commonly due to non-adherence to CPAP, often defined as less than
5 hours of usage per night, less than 5 nights per week or outright cessation of therapy, which
is a universal problem irrespective of ethnicity118, care setting119 and socioeconomic status120,
121

. Cited reasons for failure include misconceptions about the treatment 122, dry mouth123,

nasal stuffiness/rhinorrhea124, claustrophobia125, bloating/discomfort126 and concurrent
comorbidities like depression127 or cardiovascular disease128, 129. There may be an impact of
pressure interference that influences adherence, and there is a significant role that
prescribers and nursing staff play in facilitating adherence long-term.
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Figure 14. Typical algorithm of how OSA patients come to surgical treatment. Adapted from MacKay SG, Chan L.
Surgical approaches to obstructive sleep apnea. Sleep medicine clinics. 2016;11(3):331-41.130

39

4.2 Non-Surgical Treatment
4.2.1 Weight Loss
Lifestyle changes include options such as weight loss. Weight loss in obese patients with OSA
has been shown to improve AHI and in some cases cure their disease. Weight loss is typically
achieved via caloric restriction and exercise37, with the option of weight loss (bariatric)
surgery in those who fail conservative measures 129, 131.

4.2.2 Positional Therapy
A subset of patients with OSA have the majority of apnoeic events in a supine position. Such
patients are suitable for positional therapy to prevent them from rolling onto their back. The
“tennis-ball technique” is a rudimentary option where a tennis ball can be sewn onto a
patient’s pyjamas, causing discomfort and encouraging repositioning into the lateral or prone
position132. Long-term compliance is poor133, which has led to the development of novel
devices including the Sleep Position Trainer134, BuzzPod135 and NightShift136. These are
vibrotactile devices worn either on the chest or neck that can detect supine positioning and
vibrate to notify the wearer to reposition themselves. Compliance for these is better than the
tennis-ball technique137, 138. These devices can additionally monitor sleep time, body position
and snoring.

4.2.3 Mandibular Advancement Splints
MAS is a therapy for patients who fail with or decline CPAP, or perhaps with less significant
OSA. These are fitted by accredited dentists using custom made impressions. They are
comprised of two plates that fit both upper and lower dental arches, with a coupling
mechanism to prevent posterior movement of the mandible while allowing mouth opening.
There is also a screw to enable titration of the splint to achieve the largest tolerable treatment
effect. Studies have shown improvements in AHI and acceptable tolerance10. MAS can be
combined with other devices including CPAP and positional therapy.
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Typical side effects include jaw discomfort, tooth tenderness and excessive salivation as a
result of MAS wear139, 140. Patients will often require an adaptation period to the device that
can sometimes last for months10,

140

. Side effects are comparable in severity to those

experienced by CPAP users123, 129.

4.3 Surgery for OSA
There is a plethora of published surgical techniques that have been utilised in patients with
OSA. Surgery is mainly a salvage treatment when other options have failed20, and should be
used in patients who have favourable anatomy or specific deformity. Any surgery carries with
it perioperative risk, and the presence of OSA is itself an independent risk factor for increased
complications and may mandate a higher level of perioperative care 141, 142. Surgery is often
considered in “levels” and in “phases”. Levels refer to the anatomical location where the
surgery is directed, such as the retropalatal, retroglossal airway or multilevel. Phases refer to
separate operations, such as in the instance when operating on multiple levels can pose too
great a cumulative risk on post-operative complications, so procedures are staged into
different operations to facilitate recovery in-between130, 143. Definitive treatment is complete
upper airway bypass with tracheostomy, which is utilised rarely 144.

This section is divided into nasal surgery (and medical treatment), upper airway surgery (soft
tissue), maxillofacial surgery (hard tissue – maxilla and mandible) and weight loss surgery.

4.3.1 Nasal Treatment
While treatment of the nose is not intended to cure OSA, it can often provide improvements
to PSG parameters and patient-perceived quality of life as a supplement to primary
treatment, often by reducing the pressures required via CPAP145 or providing improvements
in sleep parameters including ESS and RDI146. The most frequently employed operations are
nasal valve surgery, turbinoplasty and septoplasty which are often used as “pre-phase”
surgery to facilitate delivery of CPAP11, 130. Other operations include functional endoscopic
sinus surgery, polypectomy and adenoidectomy. In patients with concomitant allergic rhinitis,
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intranasal steroids and leukotriene receptor agonists have also been demonstrated to
improve some PSG parameters111.

4.3.2 Upper Airway Surgery
The first line treatment for OSA in children is adenotonsillectomy, due to the relative size of
tonsillar tissue in the paediatric airway109. In adults tonsillar tissue constitutes a target for
upper airway surgery, particularly in patients with tonsillar hypertrophy. Tonsillectomy is
often incorporated as part of uvulopalatopharyngoplasty (UPPP), which is used to reposition
the soft palate. There are various iterations and variations of UPPP, although contemporary
modifications focus on repositioning the palate without resecting functional tissues13, 20, 147150.

Transpalatal advancement in patients who require anterior re-positioning of the palate in

conjunction with a UPPP might be performed15, 151.

Table 2. Sample of procedures used in upper airway surgery. Adapted from MacKay SG, Chan L. Surgical
approaches to obstructive sleep apnea. Sleep medicine clinics. 2016;11(3):331-41.130

Traditional Procedures
• Tonsillectomy
• Adenoidectomy
• UPPP
• Geniotubercle advancement
• Hyoid suspension
• Epiglottopexy

Contemporary Procedures
• Modified or variant UPPP
• Expansion sphincteroplasty
• Uvulopalatal flap
• Lateral palatoplexy
• Transpalatal advancement
• Radiofrequency systems
• Coblation channelling
• Midline glossectomy
• Submucosal linguoplasty
• Lingual tonsillar reduction
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Figure 15. Surgical technique for the Australian variant of contemporary UPPP. Adapted from MacKay SG,
Carney AS, Woods C, Antic N, McEvoy RD, Chia M, et al. Modified uvulopalatopharyngoplasty and coblation
channeling of the tongue for obstructive sleep apnea: a multi-centre Australian trial. Journal of Clinical Sleep
Medicine. 2013;9(02):117-24.13

Surgery to achieve tongue reduction in patients with macroglossia can be accomplished with
various techniques. Radiofrequency tongue “channelling” is used to achieve submucosal
reduction in the intrinsic tissue of the tongue13, 20. Lingual tonsillectomy or tonsil reduction is
used in patients with bulky lingual tonsil. This can be achieved with suction diathermy or
coblation. There are also other mucosal sparing surgeries 18, 19 and new robotic techniques152
that have been developed. Recently, multilevel upper airway surgery incorporating a
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combination of modified UPPP and radiofrequency to the tongue has been shown effective
in improving PSG measures and patient-reported sleepiness20.

4.3.3 Maxillofacial Surgery
Whilst upper airway surgery reduces or repositions soft tissue in order to achieve a larger
airway, maxillofacial surgery can be used to expand the entire facial unit to create a larger
airway153. It is generally reserved for those patients who either are refractory to phase 1
surgical procedures or have significant craniofacial features such as retrognathia,
micrognathia or maxillary hypoplasia154. Various forms exist, including maxillomandibular
advancement (also known as bimaxillary) surgery155.

4.3.4 Weight Loss Surgery
Bariatric surgery can be utilised in the morbidly obese for OSA and reliably reduces AHI131.
While particularly effective at reducing BMI and mitigating risk associated with obesity such
as diabetes mellitus, it will not always produce complete obliteration of the disease and may
not be superior to non-surgical weight loss37, 156. It is mostly recommended in patients with
concomitant OSA and obesity. Interventions include gastric bypass131, 157.
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Chapter 2
Phenotyping in OSA
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1. AHI – A Poor Surrogate Marker of OSA Disease Severity
A recent study158 and further validation papers in international cohorts159, 160 have proposed
a new method of clustering patients according to their symptomatology, and found that the
defined clusters responded very differently to treatment with CPAP. One cluster breakdown
from the Sleep Apnoea Global Interdisciplinary Consortium (SAGIC) proposes five main
groups; (1) those who exhibit disturbed sleep, (2) those who are minimally symptomatic, (3)
patients with both upper airway symptoms and sleepiness, (4) patients with dominant upper
airway symptoms and (5) patients with dominant sleepiness symptoms159. Each of these
symptom clusters were associated with different secondary outcomes, summarised in figure
14.

All clusters of patients had equivalent AHIs on conventional PSG, yet displayed a large
variation in symptomatic burden and secondary outcomes. This large population study
highlights the weakness of AHI as the surrogate metric in OSA and further supports the need
for a more personalised approach to the disease.

Figure 16. Profiles of the five optimal OSA clusters in the International SAGIC Sample. The relative symptom
burden is shown as a heatmap, ranging from low burden (blue) to high burden (red). Adapted from Keenan BT,
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Kim J, Singh B, Bittencourt L, Chen N-H, Cistulli PA, et al. Recognizable clinical subtypes of obstructive sleep apnea
across international sleep centers: a cluster analysis. Sleep. 2018;41(3):zsx214. 159
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2. The New Phenotype Paradigm
The push for personalised medicine in OSA is encapsulated in the P4 medicine model
(personalised, predictive, preventative and participatory) 161. It is apparent that the
measurements of AHI, ODI and Lsat are not sufficient to identify how patients respond to
treatment nor the long-term implications of untreated disease. Sleep researchers are turning
to the model of phenotyping OSA in order to better understand and treat traits that are
expressed differently in each patient.

In respiratory medicine, the terms “endotyping” and “phenotyping” have been used in varied
ways when describing the mechanisms of disease in asthma 162, bronchiolitis163, chronic
obstructive pulmonary disease (COPD) and bronchiectasis164. In OSA, endotyping refers to the
process of polysomnographic measurement to derive pathophysiological processes165 while
phenotyping refers to the manifestation of these processes as an observable attribute of the
airway as it relates to OSA23. In essence, endotyping is used to identify phenotypes.

The main contributing factors that have been identified in the pathogenesis of OSA thus far
can be summarised into at least 4 unfavourable phenotypes: 1 anatomical and 3 nonanatomical23, 166-168.

1. A small, vulnerable or collapsible airway (measured by PCRIT),
2. Low respiratory arousal threshold,
3. High loop gain (a large compensatory ventilatory response to airflow disturbance), and
4. Poor muscle responsiveness during sleep (measured by genioglossus activity).

Eckert et al found the prevalence of patients with non-anatomical, unfavourable phenotypes
contributing to OSA was 69%, suggesting that large proportion of patients were not being
optimally treated168.

Airway collapsibility is the most significant of the phenotypes by the definition of the disease
– patients with a non-collapsible airway will never have OSA, while patients with a highly
collapsible airway will have severe OSA and will invariably require treatment. In the group of
48

patients who have a moderately collapsible airway (“vulnerable”) there is some variation on
the burden of disease and this is where the significance of the other 3 phenotypes becomes
apparent.

Figure 17. Relationship of anatomical (airway collapsibility) to non-anatomical, unfavourable phenotypes (low arousal
threshold, high loop gain, poor muscle responsiveness).

Cortical arousal during sleep may be vital in restoration of normal airflow and correcting
blood-gas instability at the conclusion of an obstructive apnoea. However, there are some
deleterious after-effects of arousals that contribute to destabilisation of sleep. This includes
prevention of progression to deeper and more stable stages of sleep, excessive reductions in
pCO2 and subsequent reduction in respiratory drive169. Patients who have low arousal
thresholds are more frequently woken from sleep and experience more sleep fragmentation.
Conversely, a patient with a high arousal threshold may not be woken during a time of need,
such as during hypoxaemia. There may be a benefit in achieving balance between the positive
and negative effects of arousal from sleep.

Loop gain is a phrase borrowed from engineering which refers to the stability of a system that
is controlled by negative feedback170. In OSA, a high loop gain system has a large corrective
ventilatory response to an airflow disturbance. Over time, repeated stimulation will lead to
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larger and larger responses, excessive respiratory effort and greater swings in intrathoracic
pressure. A low loop gain system will have minimal fluctuations in ventilatory drive and likely
result in stable breathing. However, an excessively low loop gain may result in sustained
hypoventilation and subsequent blood-gas disturbances (such as in obesity hypoventilation
syndrome)171.

Muscle activity has been shown to have differing effects during sleep. Muscle responsiveness
is mediated by upper airway mechanoreceptors that detect abnormal intraluminal
pressure172, and peripheral and central chemoreceptors that detect hypercapnia173. In
patients with OSA, muscle hypotonia is more likely to produce obstruction particularly during
REM sleep. Those who belong to the subset of patients with poor muscle responsiveness are
at higher risk of apnoeic events, particularly those with vulnerable anatomy (e.g.
macroglossia).
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3. Measuring Phenotypic Traits
Phenotypic traits can be measured using the PSG with application of CPAP titration
techniques and mathematical modelling166, 167. A number of important values and cut-offs
have been defined based on comparisons to the traditional metric of AHI.

The collapsibility of the airway can simply be defined with the P CRIT. This can be obtained
experimentally using “gold standard” CPAP titration studies with a mask capable of
administering positive or negative pressure. Patients are initially treated overnight at the
minimum positive pressure required to prevent inspiratory airflow limitation (therapeutic
level of CPAP in patients with OSA, or 4-5cmH2O in people without OSA). This is then followed
by a transient lowering of pressure for up to 5 breaths (potentially to negative pressures),
until the upper airway collapses. The PCRIT is the pressure difference at which the collapse
occurs, after a linear regression analysis is performed on breaths 3-5 (breaths 1-2 are not
included as lung volume changes after CPAP require 1-2 breaths to stabilise174 and can affect
upper airway collapsibility175). Eckert et al found that patients with OSA generally had a P CRIT
between -5 to +5cmH2O. A mildly collapsible airway would have a PCRIT <-2cmH2O, moderate
-2cm to +2cmH2O and severely collapsible airway >+2cmH2O168. While overall there is a
positive correlation between PCRIT and AHI, even between these PCRIT cut-offs there is a large
variation in AHI that is better explained by the presence of non-anatomical phenotypes.

Arousal threshold with CPAP titration is defined by the ventilatory pressure change at which
a cortical arousal is stimulated and observable on EEG. This pressure change is calculated as
the difference between the nadir epiglottic pressure during inspiration and end-expiration. It
is taken from the last breath just prior to the cortical arousal. In a normal person without OSA
the arousal threshold requires a minimum of -15cmH2O71. A low arousal threshold is defined
when pressures require minimal fluctuation to stimulate an arousal with a pressure difference
>-15cmH2O168, 176.
Figure 18. Respiratory arousal threshold. Note the progressive increasing swings in epiglottic pressure (Pepi)
followed by a cortical arousal, increase in genioglossus (GG) muscle activity and a ventilatory response. Adapted

51

from Eckert DJ. Phenotypic approaches to obstructive sleep apnoea–new pathways for targeted therapy. Sleep
medicine reviews. 2018;37:45-59.22

Loop gain is defined using a dimensionless integer that is calculated from the minute
ventilation (L/min) of the maximum compensatory breath after a series of breaths at a
minimally tolerable CPAP pressure. The method for obtaining this requires titration of a
patient to a therapeutic level to establish their baseline optimum pressure. Minute
ventilation is measured at this level and recorded. CPAP pressure can then be reduced to the
minimum tolerable CPAP pressure when flow-limited breathing occurs (i.e. snoring) for at
least 3 minutes168. Minute ventilation is again recorded. CPAP can then be returned to
optimum pressure and the minute ventilation is recorded from the subsequent
compensatory breaths. The loop gain is represented by the following equation (where V
refers to the minute ventilation in L/min):

𝐿𝐺 =

𝑉𝑐𝑜𝑚𝑝𝑒𝑛𝑠𝑎𝑡𝑜𝑟𝑦 − 𝑉𝑜𝑝𝑡𝑖𝑚𝑢𝑚
𝑉𝑜𝑝𝑡𝑖𝑚𝑢𝑚 − 𝑉𝑚𝑖𝑛𝑖𝑚𝑢𝑚

A high loop gain is defined as a gain greater than 5L/min in the compensatory breaths per
1L/min reduction during flow-limited breathing167.

Figure 19. Schematic representation of low (A) versus high (B) loop gain. The patient is stabilised initially for 7
breaths, then a temporary breathing disturbance occurs for approximately 3 minutes. The breathing response in
B peaks approximately 9-fold before decreasing until an apnoea occurs due to reduced respiratory drive from the
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excessive response. Adapted from Eckert DJ. Phenotypic approaches to obstructive sleep apnoea–new pathways
for targeted therapy. Sleep medicine reviews. 2018;37:45-59.22

Muscle responsiveness is measured as the function of the percentage of maximum
genioglossus activity on EMG per unit of nadir epiglottic pressure during a breath
(%GGmax/cmH2O). Both artefact-free breaths and arousals can be used to plot several points,
with the gradient of the regression fit defining muscle responsiveness. A patient with a flatter
gradient (<0.1%GGmax/cmH2O) is defined as having poor muscle responsiveness 168.

Figure 20. The calculation of genioglossus (GG) muscle response. Excellent responsiveness is shown in the blue
line (0.86% GGmax/cmH2O), compared to poor and virtually no responsiveness in the red line (0.004%
GGmax/cmH2O). Adapted from Eckert DJ. Phenotypic approaches to obstructive sleep apnoea–new pathways for
targeted therapy. Sleep medicine reviews. 2018;37:45-59.22
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The PALM scale (PCRIT, Arousal threshold, Loop gain, Muscle responsiveness) was proposed to
assist in categorising patients according to their phenotypic traits22, 168. Approximately one
quarter of patients with OSA will be PALM category 1, with features of a highly collapsible
airway that is inevitably going to require CPAP or a major anatomical intervention even if they
do have non-anatomic phenotypic traits. Almost two thirds of patients with OSA have PALM
category 2, with one third of these in category 2a not requiring non-anatomical treatment
and two thirds in 2b that may benefit from a combination of anatomic and non-anatomic
treatments. One fifth of all patients are in PALM category 3168.

Table 3. The PALM scale. Adapted from Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining
phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. American journal of
respiratory and critical care medicine. 2013;188(8):996-1004.168

PALM
Category
1

Category CutOffs
PCRIT > +2cm
H2O

2

PCRIT -2 to +2cm
H2O

2a

PCRIT -2 to +2cm
H2O without
nonanatomic
vulnerability
PCRIT -2 to +2cm
H2O with
nonanatomic
vulnerability

2b

3

PCRIT < -2cm H2O

Patient Features

Possible Treatment Targets

Highly collapsible
upper airway
Severe OSA
Moderately
collapsible upper
airway
Mostly severe OSA
Moderately
collapsible upper
airway, primarily
anatomically driven
Moderately
collapsible upper
airway and one or
more vulnerable
nonanatomic traits
Some vulnerability
to upper airway
collapse
Mild-moderate OSA

Major anatomic or mechanical
intervention likely required (e.g.
CPAP)
Candidate for one or a combination
of targeted therapies

Anatomic intervention (e.g. CPAP,
MAS, upper airway surgery,
positional therapy, weight loss)
Combination of anatomic and
nonanatomic interventions (e.g.
MAS + weight loss + oxygen or
sleep consolidation aid)
One or a combination of targeted
therapies, with nonanatomic
interventions likely to be beneficial
(e.g. oxygen, sleep consolidation
aid)

54

4. Treatment Effects for the Anatomical Phenotype and
Emerging Treatments for Non-Anatomical Phenotypes
Multiple studies have been performed evaluating the effects of anatomical treatment on
PCRIT. The use of a MAS has been shown to reduce PCRIT by an order of 2.2-2.3cmH2O63.
Traditional UPPP has been shown to reduce PCRIT by 3.3cmH2O177, while transpalatal
advancement reduces PCRIT by 8.4cmH2O178. Positional therapy with supine avoidance has
shown a 2.2cmH2O reduction in PCRIT179. Weight loss with a 17% reduction in BMI also reduced
PCRIT by 7.5cmH2O65.

It follows that these non-anatomical traits require a different approach to treatment than the
conventional anatomical interventions outlined above. Studies investigating novel agents will
be summarised below.

The aim of treating low arousal threshold is to reduce cortical responsivity, therefore
requiring a larger pressure stimulus to induce arousal. This has been achieved with hypnotic
agents that do not induce muscle relaxation (so as not to impair muscle responsiveness).
Agents that have been trialled include eszopiclone176, zopiclone180 and trazodone181. These
have been shown to achieve a 4-5cmH2O increase in arousal threshold. As discussed earlier,
it is crucial to ensure that arousal threshold is not reduced to the point of hypoventilation.

High loop gain is treated by stabilising the compensatory response to hypoventilation. Given
that the ventilatory control system is modulated primarily by CO 2 concentration, treatments
that alter and stabilise pCO2 are preferred here182. Supplemental O2 has been observed to be
effective in achieving a 50% reduction in loop gain171. Alternatively, acetazolamide has been
employed to create a 40% reduction in loop gain183.

Muscle responsiveness requires an improvement in dilator muscle function during sleep.
Upper airway muscle training is a conservative option that can achieve a 50% reduction in
AHI, but the exact mechanism and the effects on muscle are unknown184, 185. Despiramine is
a tricyclic antidepressant that mitigates the reduction of sleep-state tonic genioglossus
activity by an order of 25% and has demonstrated a reduction in P CRIT by -2-3cmH2O186, 187.
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Finally, direct hypoglossal nerve stimulation has been explored and achieves up to 50-70%
reduction in AHI188, 189. Two forms of stimulators have been published in the literature which
involve surgical implantation and application of stimulator electrodes to selective branches
of the hypoglossal nerve that only innervate dilator muscles (such as the genioglossus) 188-191.

5. Non-Invasive Endotyping
More recently, a validated method to quantify the four phenotypes using non-invasive
routine PSG192-194 has been developed without need for CPAP titration166, 167. This endotyping
model utilises EEG monitoring to assess sleep/wake staging and cortical arousals in addition
to nasal pressure (square-root transformed), providing a semi-quantitative measure of
airflow, and is comparable to the “gold-standard” method described previously.

Loop gain is quantified by the observed size of the increase in “ventilatory drive” (overshoot)
in response to an apnoea or hypopnoea. “Ventilation” refers to the uncalibrated breath-bybreath ventilation time series (tidal volume x respiratory rate) and is derived from the nasal
pressure airflow signal (square-root transformed), integrated and normalised by dividing the
mean nasal pressure in a window. This allows approximation of the eupneic (or
resting/baseline) ventilation level194. Ventilatory drive, which is essentially the intended
ventilation if the upper airway had no resistance, is calculated for each respiration by fitting
a physiologically constrained statistical model calculated from four ventilatory control
parameters (chemoreflex gain, response-time, circulatory delay, non-chemical response to
arousal – see supplementary material194). This data is fit so that the ventilatory drive signal
matches the measured ventilation signal outlined above during periods of recovery
hypoventilation after each apnoea/hypopnoea. This is done so because the ventilatory drive
and ventilation are known to be equal during these periods of recovery. A separate ventilation
model is applied to each 7 minute window of data from the PSG and the average loop gain in
this window can thus be obtained (the 7 minute duration is chosen to allow time for
approximately 10 cyclic obstructive events to occur) 194.

There are two measures of loop gain that can be obtained (LG1 and LGn). LG1 is calculated as
the response to a cyclical ventilatory disturbance that occurs once each minute. LGn is
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calculated as the response to the individual’s actual baseline cycling period, where n is the
frequency of disturbances per minute.

After calculation of the ventilatory drive the remaining phenotypes can be identified. The
arousal threshold (ArThres) is the median ventilatory drive occurring in the breaths
immediately prior to scored EEG arousals or awakening from sleep193. Upper airway
collapsibility is measured as the median level of ventilation (Vpassive) during normal (eupneic)
ventilatory drive192. Further unpublished data suggests that the minimum level of ventilation
during this period (Vmin) may also provide an alternative metric of airway collapsibility and
PCRIT. The median level of ventilation during the arousal threshold is taken as active airway
collapsibility (Vactive). The difference between Vactive and Vpassive is used to determine muscle
responsiveness (Vcomp). These phenotypes are then averaged from each 7 minute epoch
throughout the PSG to provide a single representative trait estimate for each individual.

This method of endotyping produces different units for phenotypic traits: Loop gain is
expressed as a dimensionless integer. ArThres, Vcomp, Vpassive and Vmin are expressed as a
percentage of the eupneic ventilation (Veupnea).

Table 4. Literature cut-offs for “unfavourable” and “favourable” phenotypic traits as measured using non-invasive
endotyping192-194.

Phenotypic Trait
Airway collapsibility
Vpassive (%Veupnea)
Loop gain
LG1 (dimensionless)
Arousal threshold
ArThres (%Veupnea)
Muscle responsiveness
Vcomp (%Veupnea)

Unfavourable

Favourable

< 95.5%

> 95.5%

> 0.72

< 0.72

< 120%

> 120%

< 0%

> 0%
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Figure 21. Non-invasive method of measuring OSA phenotypes. EEG and nasal pressure traces from a PSG can be used to generate the four main phenotypes. Respiratory
disturbances and subsequent ventilatory responses are used to estimate the breath-by-breath ventilatory drive. Loop gain (LG1) is the overshoot in ventilatory drive (dark
green) in response to an apnoea/hypopnoea (shaded blue). Arousal threshold (ArThres) is the median level of ventilatory drive immediately prior to an arousal, measured as
a percentage of eupneic ventilatory drive (light green). Upper airway collapsibility (Vpassive) is the median level of ventilation during periods of resting ventilatory drive (purple).
This is displayed as a percentage of the eupneic ventilation calculated from a physiologically constrained model (chemical drive). Muscle compensation (Vcomp) is taken as the
difference between ventilation at the arousal threshold (V active) and Vpassive (red). Vmin is the minimum level of ventilation as represented on the graph on the right (not marked).
Reproduced with permission.

6. Directions for Research
Understanding phenotypic traits may allow clinicians to predict patient response to, and
perhaps understand the reasons for failure of conventional treatments for OSA. There is
therefore a need for further prospective data that evaluates the relevance of phenotypic
traits in a clinical setting. To that end, we utilised the resources available within the Illawarra,
with the study based out of a multidisciplinary sleep team directing complex OSA
management. We conducted a clinically based prospective study in collaboration with sleep
physiology researchers from Monash University using the described non-invasive method of
determining phenotypic traits192-194. This allowed us to evaluate the prevalence of phenotypic
traits in our referral cohort and whether certain traits would predict treatment success.

Chapter 3
Research

1. Aims and Hypothesis
Aim: The goal of this study was to determine the diagnostic value of endotyping in patients
who undergo salvage treatment for their OSA.

Hypothesis: It would be anticipated that anatomical phenotypes (PCRIT and its surrogate
markers) will be key in predicting responders to salvage treatment pathways. Non-anatomical
phenotypes (arousal threshold, loop gain and muscle responsiveness) may account for nonresponders to treatment.

To determine this, our primary aim was to evaluate the prevalence of the four phenotypic
traits and explore the clinical effectiveness of endotyping as a means of predicting future
treatment outcomes. Treatment “success” was defined based on criteria described in the
sleep literature:

1. PSG: 50% reduction in AHI, with overall AHI <20195
2. ESS: ≥3 point reduction in ESS, with overall ESS <10196
3. FOSQ: ≥1 reduction in FOSQ88

Given that there is limited data that exists in the literature about the phenotypic effects of
non-CPAP therapy, the secondary aim of this study was to perform an exploratory analysis to
identify the impact of salvage treatment on phenotypes in a prospective clinical cohort.
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2. Methods
2.1 Study Design and Recruitment
An observational prospective consecutive study was conducted evaluating contemporary
multidisciplinary clinical pathways that are used to decide upon treatment for patients. All
participants were recruited via the Sleep Multidisciplinary Team Meeting based at the
Illawarra Sleep Medicine Centre and One Airway Clinic (Illawarra ENT Head and Neck Clinic),
which takes referrals from within the region, Sydney and interstate. Ethics approval was
obtained from the Joint University of Wollongong and Illawarra Shoalhaven Local Health
District Health and Medical Human Research Ethics Committee (2019/ETH09854).

As discussed in the aims there was no published literature at the time of this study on the
prevalence of phenotypes or the diagnostic power of endotyping in a real-world clinical
population. We aimed to achieve a power of 0.8 for sensitivity and specificity. Based on the
literature estimate of 60% success in the salvage treatment of OSA 195, a minimum overall
sample size of 32 for sensitivity and 48 for specificity was required to achieve a power of
0.885197. Due to interruption by the SARS-CoV-2 pandemic throughout 2020, recruitment
occurred over a duration of one and a half years between May 2019 and October 2020. 49
participants were recruited overall.

Table 5. Inclusion and exclusion criteria.

Inclusion criteria
1. Age ≥18 years
2. AHI ≥5 events/h
3. BMI <45

Exclusion criteria
1. Severe psychiatric disease
2. Severe medical co-morbidities restricting treatment
pathways
3. Significant sleep co-morbidities affecting phenotyping
assessment (e.g. untreated severe insomnia or
circadian rhythm disorders)
4. Significant impairment to accurate phenotyping of
sleep disorder determined by treating clinicians
5. Commercial drivers

Inclusion and exclusion criteria are outlined in table 5. Patient recruitment included new
referrals, or patients previously seen in the clinic but re-referred for failure of initial
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management. Patients were allowed to leave the study prematurely for their own reasons
but had their data collected up to that point retained for analysis. This included patients who
failed to attend subsequent follow-up appointments. Patients who experienced any
complications related to their treatment including failure of treatment and surgical
complications were also included in this study.

Figure 22. Patient clinical pathway.
A. Patient recruitment
OSA severity

Demographics

Past medical history

B. Pre-treatment OSA assessment
Dynamic airway assessment (VOTE)
(Awake +/- Asleep)

Questionnaires
(SSS, ESS, FOSQ-30)

Polysomnography (if not already performed)

C. Treatment
1. Upper airway surgery

3. Positional therapy/Weight
Loss

2. MAS

4. Nerve stimulation

5. Combination therapy

D. Post-treatment OSA assessment (3+ months)
Polysomnography (if clinically indicated)

Questionnaires (SSS, ESS, FOSQ-30)

E. Endotyping of raw polysomnographic data
Blinding of demographics and treatment phase
and modality

Pre-treatment (from B)

Post-treatment (from D where available)

At the initial clinic appointment patient data was collected including history, examination and
PSG findings (if already obtained). Basic demographic information was collected including
height, weight, age and sex. Medical comorbidities, past medical history and baseline blood
pressure were documented. Standardised examination of the airway was performed and
documented according to the VOTE classification. This included:
•

Friedman stage (tongue, palatine and lingual tonsil)

•

Palatal position

•

Assessment of dental malocclusion

•

Awake (erect and supine) with or without sleep (under general anaesthesia)
endoscopy
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Formal in-laboratory PSG was performed at the Illawarra Sleep Medicine Centre if not already
performed or if the existing PSG was not deemed of sufficient quality for clinical correlation.
In cases where this did not occur, a type 2 ambulatory study that was reviewed by a sleep
physician was also acceptable. Scoring was undertaken by a qualified sleep technician
according to the most recent iterations of the AASM scoring manual at the time of the study
(versions 2.5 and 2.6)97, 198.

Patients were then allocated to a treatment group per existing clinical protocols. The main
categories of treatment included: mandibular advancement splint (MAS), non-nasal upper
airway reconstruction surgery (Sx), positional therapy (PTx), weight loss (WL), nerve
stimulation (NS) and combination therapy (CTx) of any of the above options. Note that prephase nasal surgery was not considered a surgical treatment category due to its adjunct role
in facilitating the use of CPAP or MAS but was included in CTx. Any discussion regarding the
patient’s preferred route of management and the recommendation of the clinic team was
also documented. Those who deviated from their original treatment pathway for reasons
including second-line treatments, patient preference, non-tolerance to treatment or for other
reasons at the discretion of the treating clinicians were evaluated according to their final
pathway. This included patients who reverted to CPAP at the conclusion of their treatment.
Generalised patient characteristics and a brief outline of these treatment pathways is in table
6.
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Table 6. Main treatment groups and pathways.

Treatment group
Mandibular advancement splint (MAS)

Brief description
Referral to dentist to fit MAS (SomnoMedTM
twin block titratable devices fitted by Gold
and Platinum dental providers)
Various non-nasal options available including
mUPPP, radiofrequency tongue reduction
and transpalatal advancement

Patient characteristics
Patients with anatomy favourable to
advancement of mandible

Positional therapy (PTx)

Usage of worn positional therapy device at
night (NightShiftTM)

Patients who demonstrate significantly worse
supine compared with lateral AHI

Weight loss (WL)

Referral to dietician or exercise physiologist
for formal weight loss programme (also
includes bariatric surgery)

Patients with significantly elevated BMI and
minimal favourable anatomical features for
surgery, MAS or PT

Nerve stimulation (NS)

Implantation of hypoglossal nerve stimulator
(open loop, bilateral stimulation with
implantable component and external
stimulator)
Any use of the above options in combination,
including pre-phase nasal surgery

Patients who have failed or unwilling to trial
other salvage treatment options and meet
minimal enrolment criteria for NS clinical trial

Upper airway surgery (Sx)

Combination therapy (CTx)

Patients who fail/have failed conservative
management previously or have vulnerable
anatomical features (e.g. tonsillar hypertrophy,
macroglossia, vertical retroposed palate)

Patients who require multiple approaches to
management
Patients with nasal pathology and require
surgery to facilitate use of airway appliance

Outcomes defined prior to and following treatment included OSA severity using PSG and
patient reported outcome measures (PROMs). Key PSG parameters included:
•

Apnoea-hypopnoea index (AHI)
o Supine AHI
o Non-supine AHI

•

Apnoea index (AI)

•

Hypopnoea index (HI)

•

Oxygen desaturation index (ODI)

•

Lowest oxygen saturation (Lsat)

PROMs included SSS87, ESS86 and FOSQ88. Blood pressure recordings were obtained at the
index and subsequent PSG appointments, with the main metric of blood pressure comparison
used being the systolic (sBP) and diastolic (dBP) taken the morning after sleep.

2.2 Data and Statistical Analysis
Patient demographic data (name, date of birth) were de-identified for analysis. Data entry for
demographics, clinical examination and PSG scores was performed with Microsoft Excel
(Microsoft Corporation, WA, USA 2019). Raw PSG data obtained locally was scored using
three software options: NoxturnalTM Sleep Study Software (Nox Medical USA, GA, USA 2020),
Embla RemLogicTM PSG Software (Natus Neuro, WI, USA 2020) and ProfusionTM Sleep
Software (Compumedics Limited, VIC, Australia 2020). De-identified traces from all studies
were standardised into European Data Format and securely sent for endotyping by an off-site
sleep technician based in Monash University (VIC, Australia) blinded to treatment phase and
modality.

Endotyping was automated using MATLAB (MathWorks, MA, USA 2020). Unfavourable
phenotypic traits were defined according to published data: high loop gain as LG1 >0.72, low
arousal threshold as ArThres <120%, low muscle compensation as Vcomp <0% and high airway
collapsibility was defined as Vpassive <95.5%192-194. There are no standardised values for Vmin or
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LGn but these were analysed as surrogate markers for airway collapsibility and loop gain
respectively as well.

Statistical analysis was conducted using Prism 9.0.0 (GraphPad Software, CA, USA 2020). A pvalue of < .05 was considered statistically significant. Variables with normal distributions as
measured by Shapiro-Wilk test were compared with independent samples t-test, and those
without were compared with Wilcoxon signed rank or Mann Whitney U test. Multiple groups
comparisons were performed with one-way analysis of variance (ANOVA) or Kruskal-Wallis
test. Linear bivariate regression analysis was performed to evaluate relationships between
phenotypic traits and individual variables such as AHI, BMI, Lsat and treatment categories.
Logistic regression was utilised to determine phenotypic traits present in individuals who had
successful treatment as defined in our aims. Fisher’s exact tests were used to determine
proportions of patients who demonstrated abnormal and favourable phenotyping traits.
Correlation between traits and different variables was performed with Pearson correlation
for normally distributed data and Spearman’s rank correlation for non-normally distributed
data.
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3. Results
3.1 Baseline Characteristics
Data from 49 patients (73.5% male) were analysed. On average, the age of patients was 44
years (range 18–72) and patients were obese with BMI 31.1 kg/m2 (range 20.8–42.3). The
average patient had moderate OSA with AHI 26.2 (range 6.0–113.8), 10 had mild OSA, 17 had
moderate OSA and 22 had severe OSA.

A proportion of patients (8/49 (16.3%)) had not attended follow-up appointments at the time
of conclusion of this study (due to significant delays caused by the SARS-CoV-2 pandemic) or
were uncontactable and so were unable to attend PSG or provide PROMs. Repeat PSG after
treatment was clinically indicated and ultimately performed in 31/41 (75.6%) patients, leaving
a total of 80 potential raw PSGs available for phenotypic analysis.

3.2 History and Examination Findings
Apart from obesity, the most common reported comorbidity on history was
hypercholesterolaemia (n = 5). Four patients were on antihypertensive medication, and 4 had
a form of cardiac arrhythmia (2 atrial fibrillation, 1 supraventricular tachycardia, 1 bundle
branch block). Two patients had asthma, and 4 were current smokers. Four had depression
or anxiety.

In 10 patients the proforma for VOTE classification was not utilised as the clinical decision for
management was selected without need for dynamic manoeuvres. Airway assessment was
conducted with awake fibreoptic nasendoscopy for all other patients. Dimensions of collapse
according to the VOTE classification, palatine tonsil, lingual tonsil and palate relative to
tongue findings are summarised in table 7. Of note, 4/49 (8.2%) patients demonstrated
complete concentric retropalatal collapse and were therefore considered unfavourable for
surgery. Nearly all patients (13/14 (92.9%)) who had a significant degree of tonsillar generated
collapse (either retropalatal or oropharyngeal) had upper airway surgery. All epiglottic
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collapse was secondary to collapse either laterally from the hypopharyngeal wall, AP from
lingual tonsil or tonsillar from lower poles of the palatine tonsils.
Table 7. Prevalence of anatomical features and planes of collapse.

Anatomical features, n/49 (%)
Palatine tonsil grade
0
9 (18.4)
1
11 (22.4)
2
7 (14.3)
3
13 (26.5)
4
2 (4.1)
Lingual tonsil grade
0
2 (4.1)
1
13 (26.5)
2
9 (18.4)
3
17 (34.7)
4
1 (2.0)
Friedman tongue grade
1
3 (6.1)
2a
3 (6.1)
2b
9 (18.4)
3
20 (40.8)
4
1 (2.0)
Palate position
Oblique
3 (6.1)
Intermediate
14 (28.6)
Vertical
11 (22.4)

Dominant planes of collapse, n/49 (%)
Retropalatal/velum (direction)
Anteroposterior (AP) 7 (14.3)
Lateral
5 (10.2)
AP/lateral
14 (28.6)
Tonsillar
9 (18.4)
Concentric
4 (8.2)
Oropharyngeal (direction)
No collapse
21 (42.9)
Lateral
4 (8.2)
Tonsillar
12 (24.5)

Retroglossal/tongue (AP% of airway)
No collapse
3 (6.1)
33%
16 (67.3)
66%
17 (34.7)
100%
1 (2.0)
Epiglottis (AP% of airway)
No collapse
29 (59.2)
33%
3 (6.1)
66%
5 (10.2)

Nasal pathology as defined by any features consistent with deviated nasal septum, septal
spurs or hypertrophic turbinates was present in 20/49 (40.8%) patients. Malocclusion
secondary to distortion of the maxillary/mandibular interface such as overbite (class II),
underbite (class III), maxillary hypoplasia or micrognathia was present in 7/49 (14.3%)
patients.
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3.3 Treatment Groups
Groups were separated according to prescribed treatment modalities. The 9 patients who
had combination therapy (CTx) were also analysed according to the separate modalities of
treatment they had undergone. There were 60 total treatments, of which:
•

22 were patients who had upper airway surgery (Sx),

•

14 patients who were prescribed positional therapy (PTx),

•

10 patients who were referred for a mandibular advancement splint (MAS),

•

9 patients who were referred for a formal weight loss programme or bariatric surgery
(WL), and

•

5 patients who underwent implantation of a hypoglossal nerve stimulator (NS).

One patient who had Sx presented to hospital with a post-operative day 7 bleed. He was
admitted and observed for 24 hours with no further intervention required. Three patients (1
combination MAS/PTx, 1 PTx, 1 WL) reverted to CPAP therapy at the conclusion of the study
due to ineffective symptom control with prescribed treatment. The patient treated under the
WL pathway also obtained nasal surgery to facilitate CPAP therapy. Two patients (1 MAS, 1
PTx) remained untreated at the conclusion of the study as they had changed their mind and
did not wish to pursue the prescribed sleep appliance. These 5 (untreated and CPAP) were
included and considered as treatment “failures” for statistical analysis.

Of the 8 patients that were lost to follow-up or had their final scheduled follow-up outside
the reporting period; 2 were CTx patients (1 combination MAS/PTx/WL, 1 Sx/PT), 3 were MAS
only patients and 3 were WL only patients. As per study protocol, all data collected for these
patients until the conclusion of the study was analysed.
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Figure 23. Patient treatment groups and final clinical pathways. Red numbers have been considered treatment “failures” for statistical analysis.

49 patients
60 total treatments

40 monotherapy

7 mandibular advancement splint

1 mandibular advancement splint and positional therapy

17 upper airway surgery

1 mandibular advancement splint and weight loss

7 positional therapy

1 mandibular advancement splint, positional therapy and weight loss

5 nerve stimulator

9 combination therapy

4 weight loss

3 upper airway surgery and positional therapy
1 upper airway surgery and weight loss
1 upper airway surgery, positional therapy and weight loss
1 positional therapy and weight loss

8 lost to follow-up
3 weight loss
3 mandibular advancement splint
1 mandibular advancement splint, positional
therapy and weight loss
1 upper airway surgery and positional
therapy

6 mandibular advancement splint

41 patients completed study
49 total treatments
3 of these patients had retrial of
CPAP, 2 of these were untreated

21 upper airway surgery

12 positional therapy

CPAP
1 mandibular advancement splint and positional therapy
1 positional therapy
1 weight loss

5 nerve stimulator

5 weight loss

Untreated
1 mandibular advancement splint
1 positional therapy
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Table 8. Baseline characteristics, PSG and PROM data for all patients per treatment modality. Values are displayed as mean ± SEM for normally distributed or median
(interquartile range) for non-normally distributed data as per Shapiro-Wilk test. p-values are calculated from unpaired t-tests or Mann Whitney U test for patients within all
groups.

Treatment
Phase (PSG n)
Characteristic
Gender, M:F
Age, yr
BMI, kg/m2
sBP, mmHg
dBP, mmHg
AHI, events/h

All
Pre (49)

31.1±0.7
120.9±2.7
74.4±2.3
26.2(15.141.5)
Supine AHI, events/h 54.7(30-75.3)
Non-supine AHI,
events/h
AI, events/h
HI, events/h
ODI, events/h
Lsat, SpO2%
SSS, /9
ESS, /24
FOSQ, /20

16.2(7.230.5)
7(2.2-19.4)
14.8(7.920.4)
22.8(11.739.0)
80.5±1.3
7.7±0.2
10±0.7
15.5±0.6

p
Post (31)

MAS
Pre (10)

36:13
44±2.3
29.9±0.8
121.1±2.7
75.7±1.7
8(2.0-24.3)

.28
.97
.66
<.0001

5:5
54.3±4.3
31.5±1.6
27.6±1.3
113.8±11.7
120±12.8
67±4.7
71.3±6.9
14.2(6.4-18) 2.9(0.2-32)

.16
.43
.36
.19

14.5(0.841.8)
5.7(1.017.8)
1.5(0.2-7.0)
3(1.2-13.5)

.0001

46(7.6-62.4)

0(0-54)

.19

.003

8(6.4-21)

.004
<.0001

2.7(1.6-5.8)
10(4.6-12.2)

2.9(0.2.31
31.3)
0.6(0.1-1.0) .008 10(5.5-24.1)
1.9(0-31.0) .20 16.7(10-25.4)

7.2(1.122.9)
85.7±1.2
2.5±0.5
5±0.7
18.3±0.5

.0002

10.9(4.916.9)
84.6±1.2
7.4±0.4
8.0±1.6
17.5±1.1

.004
<.0001
.0001
.01

p
Post (4)

Sx
Pre (22)

31±1.1
123.9±4.0
75.6±3.8
32.8(25.249.2)
54.4(32.377.3)
22(12.7-32.9)

0.6(0-38.1)

.50

30(16.4-55.7)

88±3.4
4.0±4.0
4.7±2.7
19.9

.26
.08
.32
.45

78.3±2.3
7.6±0.3
9.7±0.9
14.4±1.0

p
Post (19)
18:4
33.2±3.0
31.4±1.0
122.5±3.8
76.6±2.4
8(2.4-24.2)
15.5(9.353.3)
6.6(1.323.3)
2.4(0.4-7.3)
3.4(1.812.9)
7.3(1.727.4)
84.1±1.6
2.2±0.5
5.3±0.7
17.9±0.6

.81
.81
.82
.0003
.01
.02
.002
.005
.004
.06
<.0001
.0004
.02
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Treatment
Phase (PSG n)
Characteristic
Gender, M:F
Age, yr
BMI, kg/m2
sBP, mmHg
dBP, mmHg
AHI, events/h
Supine AHI, events/h
Non-supine AHI,
events/h
AI, events/h
HI, events/h
ODI, events/h
Lsat, SpO2%
SSS, /9
ESS, /24
FOSQ, /20

PTx
Pre (14)

30.4±1.0
119.2±4.4
71.8±3.5
23.8(11.132.7)
48.1(27.561.8)
10(3.6-16.2)
4.6(0.6-8.6)
14.1(5-24.6)
16.4(11.029.4)
83.4±1.1
7.3±0.3
8.4±1.1
15.7±1.1

p
Post (7)
12:2
46.9±3.5
29.7±1.1
117.4±4.6
74±2.1
14.2(2-41)

.69
.79
.63
.36

14(0-54)

<.05

2.8(2-40)

.71

1(0-2.8)
11.8(239.7)
5.4(1.638.5)
86±2.3
3±0.8
6.5±1.6
18.4±0.4

.25
.65
.24

NS
Pre (5)

p
Post (5)

4:1
54.2±4.4
27.5±2.0
26.6±1.8
134.5±6.6
121.2±5.1
86.8±6.9
77.8±3.2
21(17.522.5(5.541.5)
27.5)
50(40.322(3.8-44.8)
59.8)
13.5(5-43.8) 11.3(4.325.4)
14(4.9-30.5) 7(3.3-19)
8.3(5-17.5)
3(1.5-15.6)

20(14.837.7)
.26
83.2±1.5
<.0001 7.8±0.8
.29
13.8±1.9
.14
15.7±2.0

WL
Pre (9)

p
Post (3)

.11 70(30-79.1)

14(0-39)

.12

3:0
55.7±1.8
33.3±3.3
109.5±2.5
65.5±9.5
16(8.460.6)
60(58-70)

.74 22(16-49.1)

8(0-40)

.38

27.5(5-50)

4(0-7)
11(0-14)

.81
.13

6.3(6-14.5)
9(2.1-46.1)

7.1(0.413.7)
88±3.1
1.3±0.8
4.8±1.1
17.0±0.7

.07

.77
.15
.25
.55

4:5
50.3±4.3
36.6±1.7
31.9±2.6
125±6.5
117±11
69.7±2.7
71.7±2.3
41(15.3-55.9) 15(0-21)

CPAP
Pre (3)

.55 2.6(0.9-13.2)
.52 26.6(9.639.7)
9.2(4.4-24.7) .22 34.3(21.448.8)
87.4±1.5
.08 77.9±2.9
7.9±0.5
11.6±1.8
15.0±1.2

.18
.52
.66
.1

11(5.559.4)
.09
80.3±5.0
<.0001 7±1.2
.03
13±4.6
.43
12.4±1.1

Abbreviations: PSG polysomnography, M:F male:female, BMI body mass index, sBP systolic blood pressure, dBP diastolic blood pressure, AHI apnoea-hypopnoea index, AI
apnoea index, HI hypopnoea index, ODI oxygen desaturation index, Lsat oxygen saturation nadir, SSS Snoring Severity Scale, ESS Epworth Sleepiness Scale, FOSQ Functional
Outcomes of Sleep Questionnaire, MAS mandibular advancement splint, Sx surgery, PTx positional therapy, NS nerve stimulation, WL weight loss, CPAP continuous positive
airway pressure.
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3.4 Demographic, Polysomnographic and Questionnaire Outcomes
The mean age of patients who underwent Sx (33.2±3.0) was significantly lower than all other
groups as determined by one-way ANOVA and Tukey post-hoc analysis (F(5,57) = 5.8, p < .05).
There were no other significant differences in age between patients who had MAS, PTx, NS
or WL.

Pre-treatment BMI was significantly greater in patients who were recommended for WL
(36.6±1.7) when compared to Sx, PTx and NS (F(5,57) = 2.9, p < .05), but not MAS (p = .17) as
measured by one-way ANOVA and Tukey post-hoc analysis.

Paired comparisons between pre-treatment and post-treatment sBP across all groups
suggested a significant improvement of 6.9±3.3mmHg as measured by paired t-test (t(18) =
2.1, p < .05). Comparisons between dBP demonstrated a mean improvement of 4.8±2.5mmHg
but this was not statistically significant (t(18) = 2.0, p = .07). There were no significant
differences in sBP or dBP in subgroup analysis for each of MAS, Sx, PTx, WL or NS.

Pre-treatment AHI was significantly different between modalities, with median AHI highest in
Sx patients and lowest in MAS patients as measured by Kruskal-Wallis test (H(6) = 16.1, p =
.007). Overall AHI improved by a median 17 (13.2-27, W = -394, p < .0001) events/h and supine
AHI by 31 (13-45, W = 275, p < .0001) events/h for all treatment groups when measured with
Wilcoxon matched pairs signed rank test. Non-supine AHI improved by 13.6 (1-18.2) events/h
(W = -230, p = .0005). Patients who had Sx had a median improvement of 26.6 (13.2-42.2)
events/h in their overall AHI (W = -166, p < .0003), 33.6 (8.9-53) events/h in supine AHI (W =
-104, p = .005) and 13.7 (0-28) events/h in non-supine AHI (W = -81, p = .02). Patients who
had PTx had a significant improvement of 23.5 (4.1-99.1) in supine AHI only (W = -24, p < .05).
No other treatment group reached a statistically significant improvement in overall, supine
or non-supine AHI on subgroup analysis with Wilcoxon matched pairs signed rank test.

All treatment groups had a median improvement of 15.9 (8-29.3) events/h in ODI when
measured with Wilcoxon matched pairs signed rank test (W = -243, p = .001). This was
significantly improved in the Sx group by 27.5 (4.6-47.5) events/h (W = -104, p = .005). No
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other subgroups demonstrated significant improvement. Lsat demonstrated a mean
improvement of 5.8±1.5% for all treatments with paired t-test (t(29)=3.9, p = .0005). Lsat in
the Sx group improved by 7.2±2.3% (t(17) = 3.1, p = .006), but no other subgroup analyses
with paired t-test were statistically significant.

SSS significantly improved in all groups by 4.8±0.5 points as measured by paired t-test (t(27)
= 10.1, p < .0001). This was consistent with improvements in subgroup analysis for Sx (5.4±0.4,
t(18) = 12.6, p < .0001), PTx (4.1±0.7, t(8) = 6.3, p = .0002) and WL (5.8±1.2, t(3) = 4.9, p = .02)
with paired t-test. MAS and NS were not analysed as there were 2 and 0 pairs of SSS data
respectively.

ESS was also significantly improved for all groups by 3.8±1.0 points when measured with
paired t-test (t(31) = 3.9, p = .0005). Paired subgroup analysis demonstrated significant
improvements in Sx (4.6±1.4, t(19) = 3.4, p = .003) only. There was an improvement in mean
scores in WL (6±2.2, t(4) = 2.8, p = 0.05), PT (2.3±1.2, t(10) = 1.9, p = .09) and MAS (5.3±2.3,
t(2) = 2.3, p = .15) but these were not statistically significant with paired t-test. NS was not
analysed as there was no paired data.

FOSQ was analysed for all groups with a mean improvement of 3.3±0.8 points by paired t-test
(t(9) = 4.0, p = .003). Given this was not consistently completed post-treatment in all groups
further subgroup analysis was not performed.

Criteria for successful treatment as defined in the aims were applied to pre- and posttreatment results for each of AHI, ESS and FOSQ scores and summarised in table 8.
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Table 9. “Successful” treatment as defined by: (1) AHI reduction >50% AND overall AHI <20, (2) ESS reduction
≥3 and (3) FOSQ reduction ≥1. Denominators depict the available pairs of pre- and post-treatment datasets
analysed.

Criteria All
AHI
20/31
(64.5%)
ESS
19/32
(59.4%)
FOSQ
7/10 (70%)

MAS
3/4 (75%)

Sx
12/19
(63.2%)
1/3 (33.3%) 13/20 (65%)

PTx
4/7 (57.1%)

6/11 (54.5%) -

4/5 (80%)

0/1 (0%)

3/4 (75%)

2/2 (100%)

6/7 (85.7%)

NS
WL
2/5 (40%) 2/3 (66.7%)

-

Abbreviations: AHI apnoea-hypopnoea index, ESS Epworth Sleepiness Scale, FOSQ Functional Outcomes of
Sleep Questionnaire, MAS mandibular advancement splint, Sx surgery, PTx positional therapy, NS nerve
stimulation, WL weight loss.

Patients who reverted to CPAP at the end of their prescribed treatment were not significantly
different in terms of age (F(5,57) = 5.8) or BMI (F(5,57) = 2.9) compared to other treatment
groups as measured by one-way ANOVA and Tukey post-hoc comparison (p > .05), nor were
they different in terms of pre-treatment AHI with Kruskal-Wallis test and Dunn post hoc
comparison (H(5) = 16.1, p > .05).

3.5 Phenotypic Traits and Baseline Characteristics
Raw data was acquired for 59/80 (73.8%) of the performed PSGs and sent for phenotyping
analysis. The remaining 21 studies were irretrievable as they had been performed outside our
institution and had either been archived or the original laboratory failed to respond to request
for transfer of data. 45/59 (76.3%) of traces were usable for endotyping, with the remaining
excluded due to missing nasal pressure traces, missing events or being a Noxturnal TM study.
With the latter, current iterations of software did not allow for export of files that were
compatible with phenotyping at the time of this study.

Endotyping was performed on the remaining 45 studies with computation of values for loop
gain (LG1 and LGn), arousal threshold (ArThres), muscle compensation (Vcomp) and airway
collapsibility (Vpassive and Vmin). Three values of each were generated according to sleep stage
and position: (1) supine only NREM sleep, (2) all supine sleep and (3) all NREM sleep. In some
studies endotyping analysis was attempted but failed due to inadequate obstructive events
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in certain positions or embedded filters within signal traces. For purposes of determining
whether each phenotype was favourable or not, these values were averaged and compared
to the definitions as outlined above.

Figure 24. Raw PSG data breakdown for phenotypic analysis.

80 total PSG
(Pre- and post-treatment)
21 irretrievable data
(external institution)
59 PSG sent for
endotyping

12 NoxTM PSG
1 no scored events
1 missing nasal pressure

45 automated analysis
3 failed analysis
(traces corrupted)
42 usable traces and
scored events
Age was compared with the four phenotypes with a significant proportional correlation
between age and muscle compensation in all NREM sleep (r2 = .21, p = .03) when measured
with Pearson correlation. There were no other significant correlations found across loop gain,
arousal threshold or airway collapsibility.

The relationship between BMI and the four phenotypes was also analysed with Pearson
correlation, with no significant correlation found across all of loop gain, arousal threshold,
muscle compensation and airway collapsibility.

Phenotypes were compared with their corresponding AHI with linear regression and graphed
(figure 22), with relationship analysed by Pearson correlation. AHI and loop gain were
proportionally related, with Pearson correlation significant for LG1 and approaching
significance for LGn (supine NREM r2 = .10, p = .08, all supine r2 = .10, p = .06, all NREM r2 =
.11, p = .05). There was a proportional relationship between AHI and arousal threshold that
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was significant. AHI and muscle compensation were significantly proportionally correlated
during supine NREM, and approached significance during other analysed sleep periods (all
supine sleep r2 = .07, p = .12, all NREM sleep r2 = .06, p = .15). Airway collapsibility was
significantly inversely proportional with AHI when measured with Vmin. When measured with
Vpassive, this was significant during all supine sleep and approached significance during supine
NREM sleep (r2 = .11, p = .07) but was not significant during all NREM sleep (r2 = .02, p = .37).

The presence of tonsillar collapse on examination was found to be associated with pretreatment Vmin <42.7 %Veupnea with logistic regression (β0 = 3.6, β1 = -0.08, p <.05). When
analysed for Vpassive, this was not significant (β0 = -0.8, β1 = -0.003, p = .93). Likewise, presence
of nasal pathology had no significant relationship to Vpassive (β0 = 1.2, β1 = -0.01, p =.6) or Vmin
(β0 = 1.3, β1 =-0.02, p = .6).
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Figure 25. Linear comparisons between AHI (all PSG) and phenotypic traits. Loop gain is represented in a) and b), arousal
threshold in c), muscle compensation in d) and airway collapsibility in e) and f). Supine NREM data points are represented in
red, all supine data points are in green and all NREM data points are in blue.
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3.6 Phenotypic Traits and Treatment
Overall values for each phenotypic measurement are summarised in table 9. Patients
generally had unfavourable loop gain and airway collapsibility, but protective arousal
threshold and muscle compensation. Median and mean arousal threshold was significantly
lower in treated patients as measured with unpaired t-test (supine NREM, t(26) = 2.1, p = .04)
and Mann Whitney U test (all supine, U = 75, p = .01, all NREM, U = 92, p = .02). Loop gain was
variable in its relation to treatment phase, muscle compensation was reduced in treated
patients compared to non-treated patients and mean airway collapsibility was higher in
treated patients compared to non-treated patients but these were not significant differences.

Table 10. Phenotypes compared between pre-and post-treatment cohorts. Values are expressed as mean±SEM
for normally distributed or median (interquartile range) for non-normally distributed data as measured by
Shapiro-Wilk test. p values are calculated from unpaired t tests or Mann-Whitney U tests.

Phenotype, unit
LG1
Supine NREM
All supine
All NREM
LGn
Supine NREM
All supine
All NREM
ArThres, %Veupnea
Supine NREM
All supine
All NREM
Vcomp, %Veupnea
Supine NREM
All supine
All NREM
Vpassive, %Veupnea
Supine NREM
All supine
All NREM
Vmin, %Veupnea
Supine NREM
All supine
All NREM

Pre-treatment (23)

Post-treatment (19)

p

0.71±0.06
0.72±0.06
0.69±0.05

0.77±0.08
0.63±0.06
0.57±0.07

.54
.36
.16

0.49±0.03
0.51±0.03
0.49±0.03

0.55±0.05
0.49±0.04
0.47±0.04

.35
.65
.63

181.1±12.5
137.3±8.1
155.4(130.5-213.7) 122(99.1-161.1)
139.2(127.7-191.3) 116.7(101.3-148.4)

.04*
.01*
.02*

39.5±8.5
21.2(7.6-42.2)
14.0(5.9-36.2)

20.2±5.9
8.0(-0.7-30.0)
5.2(3.1-19.1)

.16
.08
.14

84.5 (65.1-93.7)
84.1(63.7-93.2)
93.5(84.2-95.2)

87.7(77.2-96.7)
90.9(83.2-96.8)
95.8(87.9-99.9)

.28
.07
.13

50.4±4.8
49.9±3.8
54.1±3.6

52.6±5.7
54.1±4.4
55.7±5.4

.77
.47
.81
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Pre-treatment phenotypes were compared to each other with one-way ANOVA between loop
gain, arousal threshold, muscle compensation and airway collapsibility subgroups. There
were significant differences in loop gain (LG1, F(4,23) = 3.1, p = .03, LGn, F(4,23) = 3.3, p = .03)
between treatment subgroups identified (figure 23, supplementary material table A). In pretreatment patients who had PTx, Vmin was significantly lower in all supine by 5.0±1.7 %Veupnea
(t(7) = 3.0, p = .02) and supine NREM sleep by 4.6±1.0 %Veupnea (t(6) = 4.8, p = .003) when
compared to all NREM sleep with paired t-test, consistent with improved airway collapsibility
during non-supine sleep. There were no other significant differences between sleep stage or
position identified within Vpassive, ArThres or loop gain phenotyping for patients treated with
PTx.

Figure 26. Pre-treatment phenotypic traits (averaged from supine NREM, all supine and all NREM sleep) per
treatment group. Dotted line represents cut-off value for favourable traits (LG1 <0.72, ArThres >120%, Vcomp
>0%, Vpassive >95.5%). Lines and error bars are mean±SEM.

Post-treatment phenotypes were also compared to each other with one-way ANOVA and
Tukey post-hoc analysis, although these were not significantly different for any of loop gain,
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arousal threshold, muscle compensation and airway collapsibility (supplementary material
figure A).

Paired pre- and post-treatment analysis was also performed. As a result of loss of usable
traces as outlined in the previous section, there were only 9 complete pairs of PSGs that had
undergone phenotypic analysis (5 Sx, 4 NS).

Paired subgroup analysis of Sx (figure 24) revealed significant improvements in loop gain
during all supine sleep, manifest in both LG1 with -0.46±0.13 (t(4) = 3.5, p = .03) as well as LGn
with -0.19±0.05 (t(4) = 3.9, p = .02) when measured with paired t-tests. This was not significant
when treatment phases were compared during all NREM or supine NREM sleep. Muscle
compensation and arousal threshold were not significantly impacted by surgery with paired
analysis, although post-operative patients as a cohort had significantly lower ArThres than
pre-operative patients by 80.5±30.0 %Veupnea when measured with unpaired t-test (t(13) = 2.7,
p = .02). Interestingly, Vpassive and Vmin did not significantly improve with paired t-tests,
although post-operative patients had a significantly higher Vpassive on average by 31.4±11.6
%Veupnea compared with pre-operative patients as measured by unpaired t-test (t(14) = 2.7, p
= .02).

Paired subgroup analysis of NS (supplementary material figure B) did not reveal any significant
improvements in any of loop gain, muscle compensation, arousal threshold or airway
collapsibility when measured with paired t-tests. It should be noted that post-treatment PSG
sent for nerve stimulator patients were taken at the 3-month mark post-recruitment, and
further titration of all nerve stimulator devices was required as per the manufacturer’s clinical
trial protocol before treatment was considered complete.
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Figure 27. Group comparisons between pre- and post-treatment phenotypes in Sx patients. Loop gain is represented in a)
and b), arousal threshold in c), muscle compensation in d), airway collapsibility in e) and f). Supine NREM data points are
represented in red, all supine data points are in green and all NREM data points are in blue.

Contingency analysis was performed comparing pre-treatment loop gain with treatment
success as measured by ESS. Patients with low loop gain pre-treatment had a higher chance
of treatment success than those with high loop gain but this was not significant as measured
by Fisher’s exact test (7/8 vs 4/9, p = .13). Contingency analysis could not be performed for
any other phenotypic traits for ESS or AHI, particularly because of the skewed population of
phenotypes in the Sx and NS groups (high arousal threshold, high airway collapsibility, high
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muscle compensation). Only 3 paired FOSQ responses were available and precluded
contingency analysis.

To further elucidate the relationship between pre-treatment phenotypes and treatment
success, bivariate logistic regression was performed for each phenotypic measurement.
Success as defined by an AHI reduction of >50% and overall AHI <20 was not significantly
associated with any of LG1 (p = .98), LGn (p = .069), ArThres (p =.47), Vcomp (p = .94) Vpassive (p =
.68) or Vmin (p = .97).

Success as defined by ESS reduction ≥3 and total ESS <10 was analysed in a similar fashion.
Low LGn <0.64 was significantly associated with successful improvement in ESS (β0 = 5.7, β1
= -8.9, p = .03). LG1 <1.05 tended to improve ESS, although this did not reach significance (β0
= 4.0, β1 = -3.8, p = .06). Patients with lower ArThres <222.2 %Veupnea also had success in
reducing ESS (β0 = 7.1, β1 = -.03, p = .004). Lower Vcomp <55.0% Veupnea (including negative
Vcomp) was also associated with improved ESS (β0 = 3.3, β1 = 0.06, p = .01). Pre-treatment
Vpassive did not significantly impact ESS (p = .85), but Vmin > 35.7 %Veupnea approached
significance with ESS success (β0 = -4.3, β1 = 0.12, p = .06).
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4. Discussion
4.1 Key Findings
The correlation between clinical severity of OSA and phenotypic traits was consistent with
published and expected trends – with higher loop gain, high arousal threshold and increased
airway collapsibility directly proportional to increasing severity of OSA as measured by AHI24.
When utilising published cut-offs for the four phenotypic traits, this cohort tended to have
the protective traits of high arousal threshold and normal muscle compensation. Loop gain
was evenly distributed, while nearly all patients had highly collapsible airways.

Patients who underwent Sx and NS had high loop gain compared with patients who had MAS,
PTx or WL. Loop gain in supine sleep was also improved after surgical treatment, which is in
contrast to previous data in the literature that suggests high loop gain patients may not
benefit from anatomical intervention and specifically upper airway surgery 199. Patients who
were treated with PTx had higher airway collapsibility during supine sleep. Trends toward
lower loop gain, lower muscle compensation and less collapsible airways were observed in
patients who had MAS/WL.

Decreased sleepiness after treatment was linked to patients who had non-anatomical
phenotypical traits of lower loop gain, lower arousal threshold and lower muscle
compensation. Airway collapse did not have a significant influence on sleepiness.

4.2 Clinical Trends and Comparison to Literature
Patient demographics were comparable to the published literature, with similarities to
international and Australian data on the prevalence of OSA in gender ratio (73.5% males), age
(mean 44) and BMI (mean 31.1)1. The rate of treatment success within our study across all
modalities was similar to published literature values (59.4% for ESS, 64.5% for AHI) 195, 196
although improvements were seen across a wide range of clinical criteria including snoring
(as measured by SSS), supine AHI, AI, HI, ODI and Lsat that did not neatly fit into the literature
definition of “success”.
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As expected, a large proportion of patients had highly collapsible airways. Similar to published
literature, more severe AHI was associated with higher arousal threshold 193 which reduced
after treatment. Loop gain was normally distributed (with both measures of LG 1 and LGn) for
both pre- and post-treatment patients. There was a trend towards reduced muscle
compensation with treatment, which should be expected with an increase in Vpassive and
improvement in airway collapsibility. Our figures for muscle compensation seemed to be
higher on average to published literature200, but phenotypic analysis did not specifically
isolate REM sleep which would be expected to demonstrate lower Vcomp values.

In comparison to Eckert et al168 figures on phenotypic trait prevalence in a general population
of patients with OSA, there were few individual patients with “pathological” low arousal
threshold (5.8% vs 37%) and muscle compensation (5.8% vs 37%), and a large amount of
patients with “pathological” high loop gain (52.9% vs. 36%). Based on the above similarities
and differences, our subset of patients may reflect the phenotypic traits expected in a
community cohort of patients who present for salvage treatment of OSA.

Collapsibility of the airway was assessed with both Vpassive and Vmin, despite there being no
pre-defined cut-offs for what a high or a low Vmin may be. These were chosen because Vmin
theoretically should serve as a marker of complete airway collapse and may be a more
accurate representation of PCRIT than Vpassive. This theory is supported by the increased
sensitivity Vmin had to change in AHI than Vpassive in each of the analysed stages of sleep.
Notably, patients with tonsillar-generated collapse on Modified Müller manoeuvre and
Woodson hypotonic method tended to have lower Vmin than those without, which suggests
that tonsillar tissue may play a significant role in contributing to the point of critical airway
collapse. The impact of tonsillar tissue and collapse is a significant factor in the
pathophysiology of paediatric OSA where adenotonsillectomy is considered first-line
management109. As expected, presence of nasal pathology did not have a significant impact
on Vmin or Vpassive. This is consistent with accepted dogma that nasal treatment is an
adjunct/facilitatory pathway only.
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The largest treatment group within this cohort were patients who underwent Sx. Surgical
patients tended to be younger in comparison to the rest of the cohort, which would suggest
that loop gain would play a greater role in the pathogenesis of their OSA compared to older
patients who are more susceptible to airway collapsibility201. This seemed to correspond with
our findings, in that a large proportion of patients had high loop gain pre-operatively.
Importantly, our data contrasts with published literature that asserts patients with high loop
gain (>0.50)199 have a higher chance of “surgical failure” using an identical definition of
treatment “success”. Only 1 patient had a loop gain <0.5, with nearly all remaining patients
above the cut-off of 0.72, which was defined as per the literature to be unfavourable loop
gain. This data is more consistent with a recent study by Li et al202, although the cohort they
analysed was of a different ethnicity to those in our study and may not be directly comparable
to a Caucasian population200. While loop gain is classically understood to be a non-anatomical
phenotype, upper airway surgery may play an underappreciated yet significant role in
stabilising the anatomical contributions to fluctuations in ventilatory stability.

Although the breakdown of phenotypic data was not provided for patients in non-supine
sleep, patients who had supine dominant OSA and were treated with PTx had lower Vmin
during supine sleep compared to a combination of all sleep positions. This supports the notion
that these patients primarily have anatomic vulnerability depending on their sleep position,
with the other non-anatomical phenotypes seemingly having little relation to AHI in these
patients.

Patients selected for treatment with MAS tended to have lower loop gain, muscle
compensation, arousal threshold and more stable airway collapsibility as measured by Vpassive.
Although this was not significantly different to other treatments due to the small sample size
of MAS patients, it is consistent with literature that describes improved efficacy of MAS with
the above four phenotypic traits165.

BMI was demonstrated in our data to have no significant association with AHI or with any of
the phenotypic traits. Notably all patients who were recommended WL had similar
phenotypic traits to those who were treated with MAS, including lower muscle compensation,
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which is postulated to be a key factor in the pathogenesis of OSA for obese patients203.
However it is unknown whether treatment with WL would mitigate that trait.

Finally, patients who had favourable non-anatomic phenotypic traits (lower loop gain, arousal
threshold and muscle compensation) tended to have a higher chance of success in treating
sleepiness symptoms regardless of treatment modality, as measured by ESS score, while
airway collapsibility was not correlatable. In addition, there was no clear link to any
phenotypic trait in treating AHI “successfully”. This complements the SAGIC consortium
findings159; treatment of sleepiness may not be as simple as reducing AHI, and yet again
demonstrates the complex pathophysiology of OSA. This highlights a potential role for
phenotyping in pre-treatment workup of patients: it may be useful for clinicians to adequately
inform patients about expected outcomes from a symptom perspective (in addition to the
known cardiovascular and neurocognitive benefits associated with ODI or AHI reduction).

4.3 Strengths
This is the first study to prospectively analyse the prevalence of phenotypic traits in a routine
clinical cohort of patients undergoing all salvage treatments for OSA. As a result of a
prospective study design, selection bias was minimised. All patient management was
undertaken under the combined supervision of a respiratory physician and ENT surgeon, each
with subspeciality fellowship training in sleep medicine. Both were blinded to patient
phenotypic traits, thereby reducing performance bias. Endotyping was performed by an
assessor who was blinded to phase of patient treatment and modality, serving to reduce
detection bias.

4.4 Limitations
Conclusions drawn from these results must be guarded given the limited data from
phenotypic analysis available. A reasonable proportion of patients (16.3%) who failed to
attend routine clinical follow-up were treated non-surgically, and therefore a degree of
attrition bias is notable. Our study was also impacted by the unprecedented advent of the
SARS-CoV-2 pandemic, which caused repercussions with delays to routine clinical care and
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limiting clinicians to preferentially follow-up patients with more urgent conditions. This may
have reduced recruitment of patients with mild-moderate OSA, who tender to be better
candidates for non-surgical management. The pandemic also caused complete cessation of
patient recruitment, restricted the sleep laboratory from performing PSG and delayed
phenotypic analysis with our collaborators in Melbourne for a period of at least 6 months.
Unfortunately, extension of recruitment during a pandemic with an uncertain endpoint was
not deemed to be appropriate.

A large proportion of patients referred from out of the area resulted in PSG data that was
external to our sleep laboratory, and thus caused difficulties with data acquisition and
software compatibility issues. Turnover and a lack of handover in local sleep technicians at
our own laboratory impeded timely re-scoring of PSG data to the stricter standards required
by the endotyping team. The lack of compatibility of NoxTM PSG software with data sent for
endotyping was not anticipated and also precluded analysis of a proportion of patients,
however work is currently being undertaken to generate an algorithm to allow endotyping
compatibility with NoxTM PSG. In future, a dedicated local sleep research laboratory with staff
specifically trained in endotyping would greatly contribute to consistent and usable PSG data
in this increasingly important field of sleep medicine.

As expected, the majority of patients who were enrolled in this study were treated with upper
airway surgery by virtue of the Illawarra ENT Head and Neck clinic being a quaternary referral
centre for sleep surgery. As such, the majority of “polysomnographic success” was driven by
surgical outcomes. Regardless, the impact of this on selection bias is likely limited, given the
multidisciplinary nature of patient recruitment and its effectiveness in highlighting unsuitable
candidates for surgery117.

There were several patients who were prescribed MAS who had incomplete datasets due to
failure to attend follow-up or proceed with treatment. In addition, post-treatment PSGs were
not indicated for most of these patients, given the majority only had mild-moderate OSA.
Likewise, compliance with WL treatment was variable, with several patients not opting to
follow-up with dietician or exercise physiologist referrals.
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Specific mention must be made about patients who had NS treatment, as they were
simultaneously enrolled in a concurrent clinical trial with permission from the trial
investigators. As such, their outcomes are considered exploratory and are not for publication
outside of this thesis.

4.5 Future Directions
These results demonstrate that current clinical paradigms in selecting patients for salvage
OSA treatment appear to be effective at distinguishing those with favourable phenotypes.
The relationship between loop gain and surgery warrants further exploration in a larger
cohort given our data contrasts with published literature.

This study highlights a need for more prospective clinical data on the prevalence of
phenotypic traits in patients who undergo salvage OSA treatment after CPAP failure. While
our institution had a referral bias of patients who opt for surgical management, a multicentre
study with collaboration of multidisciplinary sleep clinics would be the next logical step in
providing a thorough overview of the prevalence and associations of phenotypic traits with
patient treatment success.

Our data demonstrates that phenotypic traits can be determined outside of major sleep
research centres and have clinical relevance. As the process of endotyping is increasingly
automated and can now be performed non-invasively, it is possible that it will become easier
for sleep laboratories to incorporate phenotypic trait analysis as part of their diagnostic
algorithm.

With recently published randomised controlled trial data demonstrating the effectiveness of
upper airway surgery in treating OSA using a reproducible combined palatal and tongue
procedure (modified UPPP and coblation channelling tongue) 20, there is a renewed interest
in surgical management of OSA. It is therefore increasingly important for ENT surgeons
interested in practicing in the field of sleep to understand the impact of phenotypic traits in
OSA to optimally select suitable candidates for sleep surgery.
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5. Conclusion
As the complex pathophysiology of OSA is unravelled, it is evident that a multifaceted
approach is required to manage the disease. While some centres are already incorporating a
multidisciplinary team approach and directing management according to individual patient
anatomy and PSG characteristics117, it is not the current standard of practice. This is going to
become increasingly relevant as the focus shifts to a P4 medicine approach to managing OSA
and phenotyping becomes widely available.

This study has provided some clinical context and has complemented the paucity of literature
around these newly defined phenotypes of airway collapsibility, arousal threshold, loop gain
and muscle responsiveness in a laboratory setting. There remains a gap in our knowledge in
the real-world application of phenotyping to current treatment paradigms, and thus more
research needs to be performed in community cohorts undergoing best standard of care to
further investigate the clinical utility and relevance of phenotyping.
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Appendix
1. Supplementary Tables and Figures
Table S1. Pre-treatment phenotypes according to treatment modality. Categories are expressed with (number
of phenotyped PSGs). Values are expressed as mean±SEM for normally distributed or median (interquartile
range) for non-normally distributed data as measured by Shapiro-Wilk test. p values are determined from oneway ANOVA.

Phenotype, unit
LG1
Supine NREM
All supine
All NREM
LGn
Supine NREM
All supine
All NREM
ArThres, %Veupnea
Supine NREM
All supine
All NREM
Vcomp, %Veupnea
Supine NREM
All supine
All NREM
Vpassive, %Veupnea
Supine NREM
All supine
All NREM
Vmin, %Veupnea
Supine NREM
All supine
All NREM

MAS (4)

Sx (8)

PTx (8)

NS (4)

WL (4)

p

0.38±0.07
0.42±0.03
0.47±0.03

0.90±0.11
0.91±0.12
0.82±0.11

0.63±0.08
0.65±0.08
0.66±0.08

0.74±0.10
0.71±0.09
0.72±0.11

0.59±0.09
0.59±0.09
0.55±0.08

.03

0.30±0.03
0.39±0.03
0.34±0.02

0.56±0.06
0.56±0.06
0.54±0.06

0.46±0.04
0.50±0.04
0.48±0.04

0.58±0.08
0.58±0.07
0.58±0.08

0.37±0.05
0.43±0.04
0.39±0.04

.03

162.8
136.7±20.7
142±22.6

198.6±22.4
208.9±26.4
180.7±22.1

169±18.7
166.7±17.2
149.4±14.9

171.6±28.4
160.9±18.6
170.4±28.1

144.3±17.9
139.6±18.7
131.7±21.2

.20

7.0±2.6
11.4±3.7
5.5±3.0

44.7±17.7
18.0±9.2
20.0±12.1

29.9±9.4
35.2±14.5
21.1±8.6

62.0±30.9
45.4±21.0
53.2±23.5

10.2±11.2
12.1±11.3
1.3±6.0

.19

92.1±5.8
91.9±5.6
97.1±1.0

59.3±13.0
59±12.8
77.3±8.7

87.8±3.5
88.2(71.3-93.1)
91.2±2.1

78.0±10.8
79.1±10.4
78.9±9.3

86.4±6.0
86.1±6.2
93.9±2.3

.19

60.0±7.5
58.9±5.5
64.3±6.4

47.9±6.0
47.5±7.3
44.5±5.4

47.1±6.4
46.7±5.0
50.4±5.1

67.5±6.2
44.4±16.0
66.0±4.8

51.7±4.3
51.8±5.1
57.5±5.8

.48
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Figure S1. Post-treatment phenotypic traits (averaged from supine NREM, all supine and all NREM sleep) per
treatment group. Dotted line represents cut-off value for favourable traits (LG1 <0.72, ArThres >120%, Vcomp
>0%, Vpassive >95.5%). Lines and error bars are mean±SEM.
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Figure S2. Group comparisons between pre- and post-treatment phenotypes in NS patients. Loop gain is represented in a) and
b), arousal threshold in c), muscle compensation in d), airway collapsibility in e) and f). Supine NREM data points are
represented in red, all supine data points are in green and all NREM data points are in blue.
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2. Documents for Questionnaires, Dynamic Airway
Assessment
Snoring Severity Scale (SSS)
Name:
Date:
Age (years):
Sex: M / F
Please pick the answer in each of the three questions below that best describes your
partner’s/spouse’s snoring.
Score
1. How often does your partner/spouse snore?
a. Every night
b. Snores on most nights (i.e. more than 50% of nights)
c. Snores on some nights (i.e. less than 50% of nights)
d. Snores on very rare occasions or never snores
2. How much does your partner/spouse snore?
a. Snores all the time throughout the night
b. Snores most of the time throughout the night (i.e. more than 50%
of the time)
c. Snores some of the time during the night (i.e. less than 50% of
the time)
d. Hardly snores or no snoring
3. How loud is the snore
a. Snoring can be heard throughout the floor/flat or louder with the
bedroom door closed
b. Snoring can be heard in the next room with the bedroom door
closed
c. Snoring can only be heard in the bedroom
d. There is no snoring noise

3
2
1
0
3
2
1
0
3
2
1
0

Adapted from Lim PV, Curry AR. A new method for evaluating and reporting the severity of snoring. The
Journal of Laryngology & Otology. 1999 Apr;113(4):336-40.
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Epworth Sleepiness Scale (ESS)
Name:
Date:
Age (years):
Sex: M / F
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling
just tired? This refers to your usual way of life in recent times. Even if you have not done some
of these things recently try to work out how they would have affected you. Use the following
scale to choose the most appropriate number for each situation.
DIRECTIONS: Please put an X in the box for your answer to each question. Select only one
answer for each question. Please try to be as accurate as possible. All information will be kept
confidential.
Situation
(0)
(1)
(2)
(3)
Would never Slight chance
Moderate
High chance
doze
of dozing
chance of
of dozing
dozing
Sitting and reading
□
□
□
□
Watching TV
□
□
□
□
Sitting, inactive in a public
□
□
□
□
place (e.g. a theatre or a
meeting)
As a passenger in a car for an
□
□
□
□
hour without a break
Lying down to rest in the
□
□
□
□
afternoon when
circumstances permit
Sitting and talking to
□
□
□
□
someone
Sitting quietly after a lunch
□
□
□
□
without alcohol
In a car, while stopped for a
□
□
□
□
few minutes in the traffic
Adapted from Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
sleep. 1991 Nov 1;14(6):540-5.
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Functional Outcomes of Sleep Questionnaire (FOSQ-30)
Name:
Date:
Age (years):
Sex: M / F
Some people have difficulty performing everyday activities when they feel tired or sleepy. The
purpose of this questionnaire is to find out if you generally have difficulty carrying out certain
activities because you are too sleepy or tired. In this questionnaire, when the words “sleepy” or
“tired” are used, it means the feeling that you can’t keep your eyes open, your head is droopy,
that you want to “nod off”, or that you feel the urge to take a nap. These words do not refer to
the tired or fatigued feeling you may have after you have exercised.
DIRECTIONS: Please put an X in the box for your answer to each question. Select only one
answer for each question. Please try to be as accurate as possible. All information will be kept
confidential.
(0)
(4)
(3)
(2)
(1)
I don’t do
No
Yes, a
Yes,
Yes,
this
difficulty
little
moderate
extreme
activity
difficulty
difficulty
difficulty
for other
reasons
1. Do you have difficulty
□
□
□
□
concentrating on the things
you do because you are
sleepy or tired? (P)
2. Do you generally have
□
□
□
□
difficulty remembering
things, because you are
sleepy or tired? (P)
3. Do you have difficulty
□
□
□
□
finishing a meal because you
become sleepy or tired? (P)
4. Do you have difficulty
□
□
□
□
□
working on a hobby (e.g.
sewing, collecting,
gardening) because you are
sleepy or tired? (P)
5. Do you have difficulty
□
□
□
□
□
doing work around the house
(e.g. cleaning house, doing
laundry, taking out the
trash, repair work) because
you are sleepy or tired? (A)
6. Do you have difficulty
□
□
□
□
□
operating a motor vehicle for
short distances (less than
100km) because you become
sleepy or tired? (V)

7. Do you have difficulty
operating a motor vehicle for
long distances (greater than

(0)
I don’t do
this
activity
for other
reasons
□

(4)
No
difficulty

(3)
Yes, a
little
difficulty

(2)
Yes,
moderate
difficulty

(1)
Yes,
extreme
difficulty

□

□

□

□
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100km) because you become
sleepy or tired? (V)
8. Do you have difficulty
getting things done because
you are too sleepy or tired to
drive or take public
transportation? (P)
9. Do you have difficulty
taking care of financial
affairs and doing paperwork
(e.g. writing checks, paying
bills, keeping financial
records, filling out tax forms,
etc) because you are sleepy
or tired? (P)
10. Do you have difficulty
performing employed or
volunteer work because you
are sleepy or tired? (P)
11. Do you have difficulty
maintaining a telephone
conversation, because you
become sleepy or tired? (P)
12. Do you have difficulty
visiting with your family or
friends in your home because
you become sleepy or tired?
(S)
13. Do you have difficulty
visiting with your family or
friends in their home
because you become sleepy
or tired? (S)
14. Do you have difficulty
doing things for your family
or friends because you are
too sleepy or tired? (A)

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

(4)
No

(3)
Yes, a
little
□

(2)
Yes,
moderately
□

(1)
Yes,
extremely
□

(4)
No
difficulty

(3)
Yes, a
little
difficulty

(2)
Yes,
moderate
difficulty

(1)
Yes,
extreme
difficulty

□

□

□

□

15. Has your relationship
with family, friends or work
colleagues been affected
because you are sleepy or
tired? (A)

16. Do you have difficulty
exercising or participating in

□

(0)
I don’t do
this
activity
for other
reasons
□
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a sporting activity because
you are too sleepy or tired?
(A)
17. Do you have difficulty
watching a movie or
videotape because you
become sleepy or tired? (V)
18. Do you have difficulty
enjoying the theatre or a
lecture because you become
sleepy or tired? (V)
19. Do you have difficulty
enjoying a concert because
you become sleepy or tired?
(V)
20. Do you have difficulty
watching TV because you are
sleepy or tired? (V)
21. Do you have difficulty
participating in religious
services, meetings or a group
or club, because you are
sleepy or tired? (V)
22. Do you have difficulty
being as active as you want
to be in the evening because
you are sleepy or tired? (A)
23. Do you have difficulty
being as active as you want
to be in the morning because
you are sleepy or tired? (A)

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

(4)
No
difficulty

(3)
Yes, a
little
difficulty

(2)
Yes,
moderate
difficulty

(1)
Yes,
extreme
difficulty

□

□

□

□

□

□

□

□

(4)
High
□

(3)
Medium
□

(2)
Low
□

(1)
Very low
□

(4)
No

(3)
Yes, a
little

(2)
Yes,
moderate

(1)
Yes,
extreme

(0)
I don’t do
this
activity
for other
reasons
24. Do you have difficulty
being as active as you want
to be in the afternoon
because you are sleepy or
tired? (A)
25. Do you have difficulty
keeping pace with others
your own age because you
are sleepy or tired? (A)

26. How would you rate your
general level of activity? (A)
(0)
I don’t do
this for
other
reasons
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27. Has your intimate or
sexual relationship been
affected because you are
sleepy or tired? (I)
28. Has your desire for
intimacy or sex been affected
because you are sleepy or
tired? (I)
29. Has your ability to
become sexually aroused
been affected because you
are sleepy or tired? (I)
30. Has your ability to have
an orgasm been affected
because you are sleepy or
tired? (I)

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

□

Adapted from Weaver TE, Laizner AM, Evans LK, Maislin G, Chugh DK, Lyon K, Smith PL, Schwartz AR,
Redline S, Pack AI, Dinges DE. An instrument to measure functional status outcomes for disorders of
excessive sleepiness. Sleep. 1997 Oct 1;20(10):835-43.
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DYNAMIC AIRWAY ASSESSMENT
RESEARCH PROJECT:
The role of phenotyping in the personalised management of OSA
Name:
Age (years):
Clinician (initials):

Date:
Sex: M / F

Awake or asleep dynamic assessment (please circle one):
AWAKE
ASLEEP

Structure

VOTE classification (0% / 33% / 66% / 100%):
Configuration
A-P
Lateral

Concentric

Lingual tonsil grade (please circle one):
II
III

IV

Velum
Oropharynx
Tongue base
Epiglottis

I

I (horizontal)

Palate classification (please circle one):
II (intermediate)
III (vertical)

0

Palatine tonsil grade (please circle one):
I
II
III

I

Friedman tongue grade (please circle one):
IIa
IIb
III

IV

IV

Nasal pathology:

Other comments on anatomy:

114

3. List of Presentations and Publications during Candidature
Presentations
Lam ME, Kitipornchai L, Ball N, Sarkissian L, Sands T, Grundy L, MacKay SG. Incidence of
Allergen Specific and Total IgE Positivity in Children Undergoing Adenotonsillectomy. Sleep
DownUnder, October 2019. Australasian Sleep Association. (Oral and poster)

Lam ME, Roberts ST, Hayward NJ, Thompson M, Kitipornchai L, Clanfield M, Jones AC,
MacKay SG. Long-Term Adherence with New Generation Positional Therapy in Treatment of
Obstructive Sleep Apnoea. ASOHNS ASM, March 2020. Australian Society of Otolaryngology
Head and Neck Surgery. (Oral)

Lam ME, Kitipornchai L, MacKay SG. PANtonsillectomy for Obstructive Sleep Apnoea.
ASOHNS ASM, March 2020. Australian Society of Otolaryngology Head and Neck Surgery.
(Poster)

Lam ME, Kirstensen H, Kitipornchai L, MacKay SG. Subglottic Plasma Cell Mucositis – An
Interesting Case of Management. ASOHNS ASM, March 2020. Australian Society of
Otolaryngology Head and Neck Surgery. (Poster)

Lam ME, Jones AC, Edwards BA, Mann D, Sands T, MacKay SG. The Role of Phenotyping in
Salvage Therapy for OSA. ASOHNS ASM, August 2021. Australian Society of Otolaryngology
Head and Neck Surgeyr. (Oral)

Publications
Kristensen H, Lam ME, MacKay SG. Subglottic plasma cell mucositis: a case study
highlighting challenge in management. May 2020. ANZ Journal of Surgery.

115

Lam ME, Kitipornchai L, Chan L, Creber NJ, Hayward NJ, Jones AC, Petersen AJ, Sarkissian L,
MacKay SG. Assessment of macroglossia as a cause of failed continuous positive pressure
adherence. July 2020. Australian Journal of Otolaryngology.

Sideris AW, Ghosh N, Lam ME, MacKay SG. Peritonsillar abscess and concomitant COVID-19
in a 21-year-old male. September 2020. BMJ Case Reports.

Sideris AW, Wallace G, Lam ME, Kitipornchai L, Lewis R, Jones AC, Jeiranikhameneh A,
Beirne S, Hingley L, MacKay SG. Smart polymer implants as an emerging technology for
treating airway collapse in obstructive sleep apnoea: a pilot (proof of concept) study.
October 2020. Journal of Clinical Sleep Medicine.

116

